



PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
FACULDADE DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO BIOLOGIA CELULAR E MOLECULAR

LEONARDO ASTOLFI ROSADO

**A ENZIMA CHIQUIMATO QUINASE
(EC 2.7.1.71) DE *MYCOBACTERIUM TUBERCULOSIS*
COMO ALVO PARA O DESENVOLVIMENTO DE
DROGAS**

Porto Alegre
Abril, 2013

PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
FACULDADE DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO BIOLOGIA CELULAR E MOLECULAR

**A ENZIMA CHIQUIMATO QUINASE
(EC 2.7.1.71) DE *MYCOBACTERIUM TUBERCULOSIS* COMO ALVO PARA
O DESENVOLVIMENTO DE DROGAS**

Tese apresentada ao Programa de Pós-graduação em Biologia Celular e Molecular da Pontifícia Universidade Católica do Rio Grande do Sul como requisito para obtenção do grau de Doutor.

Leonardo Astolfi Rosado

Orientador:
Prof. Dr. Luiz Augusto Basso

Porto Alegre
Abril, 2013

PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
FACULDADE DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO BIOLOGIA CELULAR E MOLECULAR

**A ENZIMA CHIQUIMATO QUINASE
(EC 2.7.1.71) DE *MYCOBACTERIUM TUBERCULOSIS* COMO ALVO PARA
O DESENVOLVIMENTO DE DROGAS**

Tese apresentada ao Programa de Pós-graduação em Biologia Celular e Molecular da Pontifícia Universidade Católica do Rio Grande do Sul como requisito para obtenção do grau de Doutor.

Aprovada em _____ de _____ de _____.

BANCA EXAMINADORA:

Dr. Cristiano V. Bizarro (PUCRS-PPGBCM)

Dr. Rafael A. Caceres (PUCRS-PPGCC)

Dr. Jeverson Frazzon (UFRGS-ICTA)

"It's a Long Way to the Top If You Wanna Rock 'n' Roll"

(AC/DC)

Agradecimentos

Primeiramente eu gostaria de agradecer ao meu orientador, o professor Luiz Augusto Basso pelo apoio durante os anos em que trabalhamos juntos, sempre incentivando e orientando em busca do conhecimento científico e na minha formação como pesquisador e pessoa.

Eu gostaria de agradecer a todos os meus colegas de laboratório pela ajuda, incentivo, amizade e companheirismo, principalmente aos colegas Anderson Jader, Ardala Breda, Bruno Abaddi, Christiano Ev Neves, Claudia Paiva Nunes, Daniel Lorenzini, Diana Rostirola, Guilherme Petersen, José Eduardo Nunes, Leonardo Martinelli, Luís Timmers, Paulo Patta, Priscila Wink, Rafael Guimarães, Rodrigo Ducati, Thiago Milech, Valnês Jr. e Zilpa Adriana. Eu quero agradecer especialmente a Natasha, Manuel e Rafael Munareto pelo companheirismo e amizade durante estes anos e por sempre estarem dispostos para qualquer tipo de ajuda.

Eu gostaria de fazer um agradecimento especial ao Dr. Cristiano Bizarro, por tudo que ele me ensinou e ajudou desde o início da nossa amizade, com muita paciência, sabedoria, conhecimento, ética e paixão pela ciência.

Eu quero agradecer aos meus amigos de fora do meio acadêmico, que sempre estiveram do meu lado mesmo antes deste projeto e sempre me incentivaram e estiveram presentes durante os momentos bons e ruins.

Não esquecendo da pessoa que sempre esteve ao meu lado, ajudando, incentivando, com carinho e dedicação, a minha namorada Daiana Renck, que mesmo nos momentos mais complicados me ajudou a achar uma resposta para as minhas dúvidas, tanto no meio pessoal como profissional, sempre amável e compreensiva. Não tenho palavras pra dizer tudo que gostaria, então, resumidamente, eu te amo.

E por fim, mas não menos importante, eu gostaria de agradecer a minha família, que sempre me apoiou incondicionalmente e sempre esteve ao meu lado. Eu gostaria de agradecer especialmente ao meu sobrinho Benjamin, que nasceu alguns dias antes da prova do doutorado, e desde que chegou só trouxe alegrias.

Resumidamente, obrigado a todos!

Resumo

A tuberculose se mantém como uma das principais causas de mortalidade ao redor do mundo devido a um único agente infeccioso, o *Mycobacterium tuberculosis*. O gene *aroK* que codifica a enzima Chiquimato quinase de *Mycobacterium tuberculosis* (*MtSK*), que se mostrou essencial para a sobrevivência do bacilo, catalisa a transferência de um grupo fosforil do ATP para o chiquimato (SKH), resultando em chiquimato-3-fosfato e ADP. O presente trabalho apresenta a purificação da proteína *MtSK* até a homogeneidade e a determinação de seu estado oligomérico em solução. Estudos bioquímicos e biofísicos apresentados nesta tese sugerem que a reação catalisada pela *MtSK* monomérica segue um mecanismo de equilíbrio rápido ordenado aleatório na adição dos substratos e uma liberação ordenada sequencial dos produtos. A análise por calorimetria de titulação isotérmica (ITC) das interações não covalentes da enzima *MtSK* com diferentes ligantes resultou na determinação de assinaturas termodinâmicas para cada um desses eventos de ligação. A comparação entre as constantes de afinidade obtidas por espectrofotometria e ITC demonstraram que o ATP não aumenta a afinidade da proteína *MtSK* pelo SKH. Além disso, foi determinada em $+ 3,2 \text{ kJ mol}^{-1}$ a energia livre de acoplamento do SKH ao complexo binário *MtSK*: Mg^{2+} +ATP, sugerindo que o ATP possui uma cooperatividade negativa em relação ao SKH. Esse trabalho sugere que a *MtSK* deveria ser mais apropriadamente descrita como uma chiquimato quinase do tipo II codificada pelo gene *aroL*. Adicionalmente, este trabalho demonstra a descrição termodinâmica do SKH se ligando a *MtSK* aonde os resultados sugerem o número de prótons que estão sendo trocados durante a interação bimolecular. O valor negativo encontrado para a capacidade calorífica em pressão constante (ΔC_p) e o modelo molecular por homologia criado sugerem uma pronunciada contribuição na

dessolvatação de grupos apolares relacionados à formação do complexo. As constantes termodinâmicas foram separadas na contribuição hidrofóbica e vibracional relacionadas à formação do complexo binário *MtSK:SKH*. Os resultados obtidos relacionados à transferência de prótons durante a formação do complexo binário foram analisados tendo como referência o modelo estrutural da enzima *MtSK* construído neste trabalho. De acordo com as cadeias laterais que fazem contato com o *SKH* no modelo proposto, se pode indicar que os aminoácidos Arg58 e Arg136 atuam como fonte de prótons durante a formação do complexo binário.

Abstract

Tuberculosis remains as one of the main cause of mortality worldwide due to a single infectious agent, *Mycobacterium tuberculosis*. The *aroK*-encoded *Mycobacterium tuberculosis* Shikimate Kinase (*MtSK*), shown to be essential for survival of bacilli, catalyzes the phosphoryl transfer from ATP to the carbon-3 hydroxyl group of shikimate (SKH), yielding shikimate-3-phosphate and ADP. Here we present purification to homogeneity, and oligomeric state determination of recombinant *MtSK*. Biochemical and biophysical data suggest that the chemical reaction catalyzed by monomeric *MtSK* follows a rapid-equilibrium random order of substrate binding, and ordered product release. Isothermal titration calorimetry (ITC) for binding of ligands to *MtSK* provided thermodynamic signatures of non-covalent interactions to each process. A comparison of steady-state kinetics parameters and equilibrium dissociation constant value determined by ITC showed that ATP binding does not increase the affinity of *MtSK* for SKH. In addition, there appears to be a positive free energy coupling of 3.2 kJ mol^{-1} for SKH binding to *MtSK*:Mg²⁺+ATP binary complex, which suggest that ATP displays negative cooperativity for SKH binding. We suggest that *MtSK* would more appropriately be described as an *aroL*-encoded type II shikimate kinase. Our manuscript also gives thermodynamic description of SKH binding to *MtSK* and data for the number of protons exchanged during this bimolecular interaction. The negative value for the change in constant pressure heat capacity (ΔC_p) and molecular homology model building suggest a pronounced contribution of desolvation of non-polar groups upon binary complex formation. Thermodynamic parameters were deconvoluted into hydrophobic and vibrational contributions upon *MtSK*:SKH binary complex formation. Data for the number of protons exchanged during this bimolecular interaction are interpreted in light of a

structural model to try to propose the likely amino acid side chains that are the proton donors to bulk solvent following *Mt*SK:SKH complex formation.

Lista de Abreviaturas e Siglas

ADP, adenosina 5'-difosfato;

ATP, adenosina 5'-trifosfato;

EcSK, Chiquimato quinase de *Erwinia chrysanthemi* codificada pelo gene *aroL*;

E4P, D-eritrose 4-fosfato;

ESI-MS, espectrometria de massa com ionização por *eletrospray*;

HEPES, do inglês *N-2-hydroxyethylpiperazone-N'-2-ethanesulfonic acid*;

ITC, calorimetria de titulação isotérmica;

LDH, L-lactato desidrogenase;

MDR-TB, infecção causada por cepas de *Mycobacterium tuberculosis* resistentes a múltiplas drogas;

MtSK, Chiquimato Quinase de *Mycobacterium tuberculosis*;

NADH, nicotinamida adenina dinucleotídeo reduzido;

NMP, nucleotídeo monofosfato;

PEP, fosfoenolpiruvato;

PK, piruvato quinase;

SDS-PAGE, do inglês *sodium dodecyl sulfate-polyacrylamide gel electrophoresis*;

SKH, chiquimato, [3*R*-(3 α ,4 α ,5 β)]3,4,5-tri-hidroxi-1-ciclohexano-1-ácido carboxílico;

S3P, chiquimato 3-fosfato;

TB, Tuberculose;

TDR-TB, infecção humana causada por cepas de *Mycobacterium tuberculosis* totalmente resistentes a múltiplas drogas;

Tris, tris(hidroximetil) aminometano;

XDR-TB, infecção humana causada por cepas de *Mycobacterium tuberculosis* extremamente resistentes a múltiplas drogas.

Lista de Figuras

Figura 1. Estádios de infecção causados pelo <i>Mycobacterium tuberculosis</i> .	02
Figura 2. A via do ácido chiquímico.	05
Figura 3. Reação enzimática catalisada pela enzima chiquimato quinase.	06

SUMÁRIO

Capítulo 1	1
1. INTRODUÇÃO	2
1.1 A Tuberculose	2
1.2 <i>Mycobacterium tuberculosis</i>	4
1.3 A via do ácido chiquímico	4
1.4 Chiquimato quinase	6
2. JUSTIFICATIVA	8
3. OBJETIVOS	9
3.1 Objetivo Geral	9
3.2 Objetivos Específicos	9
Capítulo 2	10
Carta de Aceite do Manuscrito	11
Artigo Aceito PLoSOne - The mode of action of recombinant <i>Mycobacterium tuberculosis</i> Shikimate Kinase: kinetics and thermodynamic analyses	12
Capítulo 3	53
CONSIDERAÇÕES FINAIS	54
Referências	57
Anexos	61
Anexo A	62
Artigo Submetido Kinetic mechanism and energetics of nucleotide binding to <i>Mycobacterium tuberculosis</i> Cytidine Monophosphate Kinase. Biophysical Chemistry, 2013.	
Anexo B	64
Artigo Publicado Biochemical characterization of uracil phosphoribosyltransferase from <i>Mycobacterium tuberculosis</i> . PLoS ONE, 2013.	
Anexo C	66
Artigo Publicado Role of Serine140 in the mode of action of <i>Mycobacterium tuberculosis</i> β - 2 ketoacyl-ACP reductase (MabA). BMC Research Notes, 2012.	

Anexo D	68
Artigo Aceito Recombinant <i>Erwinia carotovora</i> L-asparaginase II production in <i>Escherichia coli</i> fed-batch cultures. <i>Brazilian Journal of Chemical Engineering (Impresso)</i> , 2012.	
Anexo E	70
Artigo Publicado Molecular, kinetic and thermodynamic characterization of <i>Mycobacterium tuberculosis</i> orotate phosphoribosyltransferase. <i>Molecular Biosystems (Print)</i> , v. 8, p. 572, 2012.	
Anexo F	72
Artigo Publicado Pyrimidin-2(1H)-ones based inhibitors of <i>Mycobacterium tuberculosis</i> orotate phosphoribosyltransferase. <i>European Journal of Medicinal Chemistry</i> , v. Epub, p. ahead-of print, 2012.	
Anexo G	74
Artigo Publicado Wild-Type Phosphoribosylpyrophosphate Synthase (PRS) from <i>Mycobacterium tuberculosis</i> : A Bacterial Class II PRS?. <i>Plos One</i> , v. epub, p. ahead-of print, 2012.	
Anexo H	76
Artigo Publicado Molecular, kinetic, thermodynamic, and structural analyses of <i>Mycobacterium tuberculosis</i> hisD-encoded metal-dependent dimeric histidinol dehydrogenase (EC 1.1.1.23). <i>Archives of Biochemistry and Biophysics (Print)</i> , v. 512, p. 143-153, 2011.	

Capítulo 1

Introdução

1. INTRODUÇÃO

1.1 A Tuberculose

Segundo a OMS (WHO, 2012), dentre as doenças infectocontagiosas que afligem o homem, a tuberculose (TB) é uma das mais preocupantes devido a sua alta taxa de incidência, prevalência e mortalidade. Atualmente, epidemiologistas estimam que um terço da população do planeta esteja infectada pelo bacilo da TB, com uma taxa anual de aproximadamente 8,7 milhões de novos casos e 1,7 milhão de mortes por ano ocorrendo em todo o mundo (WHO, 2012) e sua infecção se dá preferencialmente pelas vias aéreas (Parrish, 1998)(Figura 1).




Figura 1. Estádios de infecção do *Mycobacterium tuberculosis*, retirado de Parrish, 1998.

Aproximadamente 95% destes casos ocorrem nas nações em desenvolvimento, onde estão relacionados aos poucos recursos disponíveis para garantir um tratamento adequado e onde a infecção pelo vírus da imunodeficiência humana (HIV) é comum. O aumento da resistência a drogas, causada pelo surgimento de novas linhagens, tem levado a uma maior necessidade em compreender os mecanismos moleculares de ação das drogas e de resistência do bacilo às mesmas. Ainda, o custo do tratamento de

pacientes com TB resistente a múltiplas drogas pode assumir valores muito mais altos que o de pacientes com TB susceptível às drogas de uso comum.

Robert Koch, em 1882, identificou uma bactéria álcool-ácido resistente, *Mycobacterium tuberculosis* (MTB), como o agente causador da TB. Em 1921, a vacina BCG foi utilizada pela primeira vez como um agente profilático contra a infecção causada pelo MTB, e é a vacina utilizada no mundo atualmente.

O descobrimento das propriedades antibacterianas de algumas drogas de primeira linha levaram a quimioterapias efetivas que diminuiram a taxa de mortalidade no mundo, e a posterior introdução de algumas outras ao arsenal utilizado para combater a TB parecem ter provido um número adequado de efetivos agentes antimicrobianos (Goodman & Gilman *et al*, 2006). A quimioterapia efetiva contra TB deve incluir uma ação primária bactericida contra organismos em rápido crescimento e uma subsequente esterilização da população de bacilos dormentes.

A moderna terapia padrão de curta duração para TB está baseada em um regime de quatro drogas que deve ser estritamente seguido para prevenir resistência a drogas e reincidência. Dessa forma, a prevenção da má administração das drogas pelo paciente é o melhor meio de garantir um tratamento efetivo e prevenir a aquisição de resistência.

Apesar da baixa permeabilidade da parede celular, que dificulta a absorção de moléculas, as micobactérias necessitam de mecanismos moleculares para obter uma resistência significativa (Cole *et al*, 1998). Mutantes de MTB resistentes a uma droga qualquer estão naturalmente presentes em qualquer grande população bacteriana, independentemente da exposição a drogas. A frequência de mutantes resistentes a rifampicina e isoniazida é relativamente alta e, portanto, a grande população extracelular de bacilos metabolicamente ativos e com rápido crescimento em lesões cavitárias conterá organismos resistentes a pelo menos uma das drogas. Conseqüentemente, a

monoterapia ou a terapia de duas drogas imprópriamente administrada selecionará mutantes resistentes a drogas que podem conferir resistência a toda população de bacilos. Em 2006, 500 000 casos de cepas resistentes foram relatados, demonstrando assim a atual situação e a gravidade do problema.

Existem duas formas de TB altamente perigosas para a saúde humana; as cepas multirresistentes (MDR) são resistentes a pelo menos isoniazida e rifampicina e requerem um tratamento quimioterápico mais extensivo com quimioterápicos de segunda linha; e as cepas de *Mycobacterium tuberculosis* extremamente resistentes a múltiplas drogas (XDR) se mostram resistentes aos quimioterápicos tanto de primeira quanto de segunda linha, indicando assim uma necessidade de desenvolver novos quimioterápicos contra a TB (Hargreaves, 2008).

1.2 *Mycobacterium tuberculosis*

O *Mycobacterium tuberculosis*, principal agente causador da TB, é uma bactéria gram-positiva com um alto conteúdo genômico de G+C. Esta bactéria se apresenta em forma de bacilo mostrando dimensões que variam de 0,3 a 0,6 µm de largura e de 1 a 4 µm de altura, possuindo uma alta complexidade em seu envelope celular e crescimento lento .

1.3 A Via do ácido chiquímico

A via do ácido chiquímico (**Figura 2**) é constituída por sete passos enzimáticos, cada um catalisado por uma enzima diferente e cada enzima é codificada por um único gene (**Ducati,2007**).




Figura 2. A via do ácido chiquímico, retirado de Ducati, 2007.

Essa via é essencial para a vida de plantas, organismos do filo apicomplexa, parasitos e bactérias (Bentley, 1990; Campbell, 2004; Roberts, 2002; Roberts, 1998; Keeling, 1999; McConkey, 1999; McConkey, 2004;), incluindo o MTB (Parrish, 2002), porém é ausente no homem, o que a torna um alvo atrativo para o descobrimento de novos fármacos contra a TB. No bacilo causador da TB, a via do ácido chiquímico tem como substratos iniciais fosfoenolpiruvato e D-eritrose 4-fosfato (E4P), tendo como produto final o corismato, que é um importante componente na síntese das vitaminas E e K, folato, ubiquinona, menaquinonas, micobactinas, naftoquinonas e dos aminoácidos aromáticos (Hermann, 1999).

1.4 Chiquimato quinase

A enzima chiquimato quinase (*MtSK*) é codificada pelo gene *aroK*, composto por 531 pb que resultam em uma proteína de 176 aa com peso molecular teórico de 18 451Da. Esta enzima catalisa a quinta reação da via do ácido chiquímico, convertendo adenosina 5'trifosfato (ATP) e chiquimato (SKH) em adenosina 5'difosfato (ADP) e chiquimato-3-fosfato (S3P), utilizando magnésio como cofator, realizando uma transferência do fosfato γ do doador (ATP) para o carbono três do anel do ácido chiquímico (**Figura 3**).




Figura 3. Reação enzimática catalisada pela enzima chiquimato quinase.

Esta enzima pertence à família de enzimas Nucleosídeo Monofosfato Quinase, sendo um importante grupo de enzimas que catalisa a transferência reversível de um fosfato,

pertencente a um nucleotídeo trifosfato, para um nucleotídeo monofosfato específico (Yan, 1999). O produto desta reação é subsequentemente fosforilado, resultando em precursores dos ácidos nucleicos. Cada membro dessa família possui três domínios conservados: o domínio Core contendo cinco folhas- β paralelas e o P-loop que formam o sítio de ligação dos nucleotídeos; o domínio LID, que se move sobre o sítio ativo e possui resíduos essenciais para a ligação do ATP; e o sítio de ligação dos nucleotídeos que possuem um fosfato (NMP), que reconhece e se liga ao nucleotídeo monofosfato. No caso da chiquimato quinase, esse sítio reconhece e se liga ao chiquimato, que é o substrato da reação (Pereira, 2004; Hartmann,2006; Dias, 2007; Dhaliwal; 2004).

2. JUSTIFICATIVA

A TB é uma doença que demonstra índices alarmantes em relação à incidência, prevalência e mortalidade em todos os continentes do mundo, o que a torna uma preocupação mundial. A rifampicina e a isoniazida, descobertas em 1966 e 1952 respectivamente, são os antibióticos mais poderosos utilizados atualmente contra a TB, entretanto, o surgimento de novas cepas resistentes ao tratamento atual e as altas taxas de incidência indicam a necessidade do desenvolvimento de novos agentes contra a TB, a fim de impedir a proliferação destas cepas resistentes, o que tornaria ainda mais difícil a luta contra esta doença. A enzima alvo deste trabalho pertence à via do ácido chiquímico, que é uma via promissora para o estudo de novos inibidores, já que esta é inexistente em seu hospedeiro (*Homo sapiens*), o que nos remete ao princípio da toxicidade seletiva. Se o produto final desta via, o corismato, for impedido de ser produzido, o bacilo da TB perderá sua viabilidade, devido à extrema importância do corismato já que ele é um dos precursores na síntese do folato, ubiquinonas, vitamina E, vitamina K e dos aminoácidos aromáticos, componentes essenciais para a sobrevivência do bacilo.

3. OBJETIVOS

3.1 Objetivo Geral

Caracterização bioquímica e biofísica da enzima *MtSK* (E.C. 2.7.1.71) codificada pelo gene *aroK* de *Mycobacterium tuberculosis* H37Rv como alvo para o desenvolvimento de novas drogas de ação seletiva.

3.2 Objetivos Específicos

-
- Expressar e purificar a enzima *MtSK*.
 - Determinar a massa molecular e sequência N-terminal da proteína.
 - Determinar as constantes cinéticas verdadeiras.
 - Determinar o mecanismo enzimático por calorimetria de titulação isotérmica e fluorimetria.
 - Determinar a variação da capacidade calorífica a pressão constante na formação do complexo *MtSK:SKH*.
 - Determinar os prótons envolvidos na formação do complexo *MtSK:SKH*.
-

Capítulo 2

The mode of action of recombinant
Mycobacterium tuberculosis
Shikimate Kinase: kinetics and
thermodynamics analyses

Leonardo Astolfi Rosado, Igor Bordin
Vasconcelos, Mário Sérgio Palma,
Vincent Frappier, Rafael Josef
Najmanovich, Diógenes Santiago
Santos and Luiz Augusto Basso.

PONE-D-12-33107R3

The mode of action of recombinant Mycobacterium tuberculosis Shikimate Kinase: kinetics and thermodynamics analyses

PLOS ONE

Dear Dr. Basso,

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE.

Your manuscript will now be passed on to our Production staff, who will check your files for correct formatting and completeness. After this review, they may return your manuscript to you so that you can make necessary alterations and upload a final version.

Before uploading, you should check the PDF of your manuscript very closely. **THERE IS NO AUTHOR PROOFING.** You should therefore consider the corrected files you upload now as equivalent to a production proof. The text you supply at this point will be faithfully represented in your published manuscript exactly as you supply it. This is your last opportunity to correct any errors that are present in your manuscript files.

In addition, now that your manuscript has been accepted, please log into EM at <http://www.editorialmanager.com/pone> and update your profile. Click on the "Update My Information" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

If you or your institution will be preparing press materials for this manuscript, you must inform our press team in advance. Please contact them at ONEpress@plos.org.

Please contact us at plosone@plos.org if you have any questions, concerns, or problems, and thank you for submitting your work to our journal.

With kind regards,
Pratul K. Agarwal
Academic Editor
PLOS ONE

The mode of action of recombinant *Mycobacterium tuberculosis* Shikimate Kinase: kinetics and thermodynamics analyses

Leonardo Astolfi Rosado^{1,3}, Igor Bordin Vasconcelos^{1,3}, Mário Sérgio Palma⁴, Vincent Frappier⁵, Rafael Josef Najmanovich⁵, Diógenes Santiago Santos^{1,2,3,*} and Luiz Augusto Basso^{1,2,3,*}

¹Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga 6681, Porto Alegre, RS 90619-900, Brazil.

²Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Av. Ipiranga 6681, Porto Alegre, RS 90619-900, Brazil.

³Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Av. Ipiranga 6681, Porto Alegre, RS 90619-900, Brazil.

⁴Laboratório de Biologia Estrutural e Zooquímica, Centro de Estudos de Insetos Sociais, Departamento de Biologia, Instituto de Biociências de Rio Claro, Universidade Estadual Paulista (UNESP), Rio Claro, SP, Brazil.

⁵Department of Biochemistry, Faculty of Medicine, Université de Sherbrooke, 3001, 12e Avenue Nord. Sherbrooke, Québec, Canada J1H 5N4.

*Corresponding authors. Telephone/Fax: +55-51-33203629.

E-mail addresses: luiz.basso@pucrs.br (Luiz A. Basso) or diogenes@pucrs.br (Diógenes S. Santos).

Abstract

Tuberculosis remains as one of the main cause of mortality worldwide due to a single infectious agent, *Mycobacterium tuberculosis*. The *aroK*-encoded *M. tuberculosis* Shikimate Kinase (*MtSK*), shown to be essential for survival of bacilli, catalyzes the phosphoryl transfer from ATP to the carbon-3 hydroxyl group of shikimate (SKH), yielding shikimate-3-phosphate and ADP. Here we present purification to homogeneity, and oligomeric state determination of recombinant *MtSK*. Biochemical and biophysical data suggest that the chemical reaction catalyzed by monomeric *MtSK* follows a rapid-equilibrium random order of substrate binding, and ordered product release. Isothermal titration calorimetry (ITC) for binding of ligands to *MtSK* provided thermodynamic signatures of non-covalent interactions to each process. A comparison of steady-state kinetics parameters and equilibrium dissociation constant value determined by ITC showed that ATP binding does not increase the affinity of *MtSK* for SKH. We suggest that *MtSK* would more appropriately be described as an *aroL*-encoded type II shikimate kinase. Our manuscript also gives thermodynamic description of SKH binding to *MtSK* and data for the number of protons exchanged during this bimolecular interaction. The negative value for the change in constant pressure heat capacity (ΔC_p) and molecular homology model building suggest a pronounced contribution of desolvation of non-polar groups upon binary complex formation. Thermodynamic parameters were deconvoluted into hydrophobic and vibrational contributions upon *MtSK*:SKH binary complex formation. Data for the number of protons exchanged during this bimolecular interaction are interpreted in light of a structural model to try to propose the likely amino acid side chains that are the proton donors to bulk solvent following *MtSK*:SKH complex formation.

Keywords: steady-state kinetics; isothermal titration calorimetry; fluorescence spectroscopy; enzyme mechanism; shikimate kinase; tuberculosis

Introduction

Tuberculosis (TB), owing to *Mycobacterium tuberculosis* infection, still remains as a major global health problem. Approximately 9 million new cases of TB are detected each year, and close to 2 million people die from the disease [1]. In 2008, it has been estimated that 390 000–510 000 cases of multidrug-resistant tuberculosis (MDR-TB, which is defined as TB caused by strains of *M. tuberculosis* that are resistant to at least isoniazid and rifampicin) emerged globally [2]. In 2008, MDR-TB caused an estimated 150 000 deaths. It has also been reported that 5.4% of MDR-TB cases were found to have extensively drug-resistant tuberculosis (XDR-TB, which is defined as MDR-TB plus resistance to a fluoroquinolone and at least one second-line injectable agents: amikacin, kanamycin and/or capreomycin) [2]. In addition, TB cases due to infection with totally drug-resistant strains (TDR-TB) have been reported [3]. The emergence of drug-resistant strains of *M. tuberculosis* has thus highlighted the need for the development of new therapeutic strategies to combat TB.

Rational inhibitor design relies on mechanistic and structural information on the target enzyme. Enzymes offer unique opportunities for drug design that are not available to cell surface receptors, nuclear hormone receptors, ion channel, transporters, and DNA [4]. It has been pointed out that one of the lessons to be learned from marketed enzyme inhibitors is that the most potent and effective inhibitors take advantage of enzyme chemistry to achieve inhibition [5]. Moreover, the recognition of the limitations of high-throughput screening approaches in the discovery of candidate drugs has rekindled interest in rational design methods [6]. Accordingly, mechanistic analysis should always be a top priority for enzyme-targeted drug programs aiming at the rational design of potent enzyme inhibitors. Moreover, targets that are both essential to survival of, and

exclusive to, *M. tuberculosis* are particularly promising as their inhibition could lead to the development of non-toxic drugs to the human host and having effective killing effect on the pathogen [7].

The biosynthesis of aromatic rings from carbohydrate precursors involves a range of chemical transformations that together constitute the shikimate pathway; through seven enzymatic steps, phosphoenolpyruvate (PEP) and D-erythrose 4-phosphate (E4P) are condensed to the branch point compound chorismate (endproduct), which leads to several additional terminal pathways [7,8]. The shikimate pathway is essential in algae, higher plants, fungi, bacteria, apicomplexan parasites and sea anemone, but absent from humans [7-16]. The mycobacterial shikimate pathway (the main trunk) leads to the biosynthesis of chorismic acid, which is converted by five distinct enzymes to prephenate (precursor of phenylalanine and tyrosine), anthranilate (precursor of tryptophan), aminodeoxychorismate (precursor of *para*-aminobenzoic acid -PABA – which, in turn, leads to tetrahydrofolate synthesis), *para*-hydroxybenzoic acid (precursor of ubiquinone or Coenzyme Q), and isochorismate (common precursor of naphthoquinones, menaquinones and mycobactins) [7].

The *aroK*-encoded *M. tuberculosis* Shikimate Kinase (*MtSK*; EC 2.7.1.71), the fifth enzyme of the pathway, catalyzes a phosphoryl transfer from ATP to the carbon-3 hydroxyl group of shikimate (SKH; [3*R*-(3 α ,4 α ,5 β)]3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid) forming shikimate 3-phosphate (S3P) (**Fig.1**). Disruption of *aroK* gene has demonstrated that *MtSK*, and thus the common aromatic biosynthesis pathway, is essential for the viability of *M. tuberculosis* [17]. We have previously reported cloning and expression in *Escherichia coli* of recombinant *MtSK* in functional form [18], thereby confirming the correct *in silico* assignment to the structural gene encoding this protein. Our research group [19,20] and others [21-23] have reported crystal structure

determinations of *MtSK*. Three functional motifs of nucleotide-binding enzymes were recognizable in *MtSK*, including a Walker A-motif (that forms the phosphate-binding loop; P-loop), a Walker B-motif, and an adenine-binding loop. *MtSK* belongs to the family of nucleoside monophosphate (NMP) kinases, which are composed of three domains: (1) the CORE domain containing the five stranded parallel β -sheet and the P-loop (residues 9-17), which forms the binding site for nucleotides; (2) the LID domain (residues glycine-112 to aspartate-124), which closes over the active site and has residues that are essential for the binding of ATP; and (3) the NMP-binding domain (residues threonine-33 to glutamate-61; also known as SB domain in *MtSK*), which functions to recognize and bind shikimate [19-22]. More recently, based on an analysis of global movements upon ligand binding, it has been proposed that *MtSK* is comprised of four domains [23]: (1) the ESB domain (extended SB; residues 32-93); (2) the nucleotide-binding (NB) site that includes the P-loop (Walker A motif, residues 9-17), the AB-loop (residues 148-155), and the segment of 101-110; (3) the LID domain (residues 112-124); and (4) the Reduced Core (RC) domain. A characteristic feature of NMP kinases is that they undergo large conformational changes during catalysis [24].

Based on a series of high-resolution crystal structures of *MtSK* in apo form and as binary and ternary complexes, it has been proposed that the enzyme mechanism is random sequential binding of SKH and ATP (adenosine 5'-triphosphate), and release of ADP (ADP, adenosine 5'-diphosphate) product is followed by S3P to generate free enzyme [23]. However, no description of *MtSK* enzyme mechanism in solution has, to the best of our knowledge, ever been described. Here we present purification of recombinant *MtSK* to homogeneity, mass spectrometry analysis, N-terminal amino acid sequencing, and oligomeric state determination of the recombinant protein. We also present true steady-state kinetic parameters determination, and ligand binding by fluorescence

spectroscopy and isothermal titration calorimetry (ITC) data. These data demonstrate that the chemical reaction catalyzed by monomeric *MtSK* follows a random order mechanism of substrate binding, and that S3P product is released first followed by ADP dissociation to yield free enzyme. The ITC results provided the thermodynamic signatures of non-covalent interactions to the binding processes. In addition, we showed that there is a positive free energy coupling of 3.2 kJ mol^{-1} for SKH binding to *MtSK*: Mg^{2+} ATP binary complex. Accordingly, ATP appears to display negative cooperativity for SKH binding. Based on experimental evidence, we propose that *MtSK* would more appropriately be described as an *aroL*-encoded type II shikimate kinase. We also present studies of the temperature dependence of thermodynamic parameters for SKH interaction with *MtSK*. The change in constant pressure heat capacity (ΔC_p) on going from free to bound states was evaluated and molecular homology model building was carried out to try to correlate complex formation with burial of surface area. Attempts were also made to deconvolute the thermodynamic parameters into hydrophobic and vibrational components. Determination of changes in binding enthalpy (ΔH) was carried out in the presence of buffers with different enthalpies of ionization. These ITC results showed that *MtSK*:SKH binary complex formation is accompanied by release of protons to the bulk solvent. Based on structural information, we suggest that the δ -guanidinium groups of Arg58 and/or Arg136 are the likely sources of proton released into solution upon binary complex formation. Understanding the mode of action of *MtSK* will inform us on how to better design inhibitors targeting this enzyme with potential therapeutic application in TB chemotherapy. The results here presented may also help chemical biologists to design function-based chemical compounds to carry out either loss-of-function (inhibitors) or gain-of-function (activators) experiments to reveal the biological role of *MtSK* in the context of whole *M. tuberculosis* cells. Accordingly, it is hoped that the results here

described may be useful to the rational design of anti-TB agents and that they may contribute to our understanding of the biology of *M. tuberculosis*.

Material and methods

Purification of M. tuberculosis Shikimate Kinase (MtSK)

The recombinant enzyme was expressed in *Escherichia coli* BL21 (DE3) host cells as previously described [18]. Approximately 6 g of cells were suspended in 24 mL of Tris-HCl (tris(hydroxymethyl)aminomethane) 50 mM pH 7.6, disrupted by sonication, and the cell debris removed by centrifugation (48,000g for 60 min). MgCl₂ was added to the supernatant to a final concentration of 10 mM followed by addition of 1 mg of DNase, stirred for 30 min at 4 °C, and centrifuged (10,000g for 30 min). Interestingly, addition of MgCl₂ resulted in precipitation of *MtSK* whereas a number of proteins remained in the supernatant. Accordingly, this step served two purposes in the purification protocol: lysis of DNA by DNase, and *MtSK* precipitation. The pellet was suspended in Tris-HCl 50 mM pH 7.6 containing KCl 500 mM, and centrifuged (10,000g for 15 min). This solution was concentrated down to approximately 20 mL, and 20 mL of Tris-HCl 50mM pH 7.6 containing KCl 500 mM and (NH₄)₂SO₄ 2M was added, resulting in a solution containing 1M (NH₄)₂SO₄. This solution was clarified by centrifugation. The supernatant was loaded on a Phenyl Sepharose 16/10 column (GE healthcare) previously equilibrated with buffer A (Tris-HCl 50mM, KCl 500mM, (NH₄)₂SO₄ 1M, pH 7.6) and the adsorbed material eluted with a linear gradient of buffer B (Tris-HCl 50mM, KCl 500mM, pH 7.6) at 1 mL min⁻¹. The protein fractions containing the *MtSK* were pooled and loaded on a Sephacryl S-100 HR column (GE Healthcare) and isocratically eluted with buffer B at 0.25 mL min⁻¹. The

fractions containing homogeneous recombinant *MtSK* were pooled, and stored in 85 % $(\text{NH}_4)_2\text{SO}_4$. Protein expression, purification and apparent homogeneity of recombinant *MtSK* was confirmed by 12 % sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) stained with Coomassie Brilliant Blue [25]. Protein concentration was determined by the method of Bradford *et al.* [26] using the Bio-Rad protein assay kit and bovine serum albumin as standard (Bio-Rad Laboratories).

Electrospray ionization mass spectrometry (ESI-MS) analysis

The subunit molecular mass of recombinant protein preparation was assessed by ESI-MS, employing some adaptations made to the system described by Chassaigne and Lobinski [27]. Samples were analyzed on a triple quadrupole mass spectrometer (model QUATTRO II) equipped with a standard electrospray (ESI) probe (Micromass, Altrincham, United Kingdom), and adjusted to a flow rate of *ca.* $250 \mu\text{L min}^{-1}$. The source temperature ($80 \text{ }^\circ\text{C}$) and needle voltage (3.6 kV) were maintained constant throughout the experimental data collection, applying a drying gas (nitrogen) flow of 200 L h^{-1} and a nebulizer gas flow of 20 L h^{-1} . The mass spectrometer was calibrated with intact horse heart myoglobin and its typical cone-voltage induced fragments. The subunit molecular mass of recombinant *MtSK* was determined by adjusting the mass spectrometer to give a peak with at half-height of 1 mass unit, and the sampling cone-to-skimmer lens voltage controlling the transfer of ions to the mass analyzer was set to 38 V. About 50 pmol (10 μL) of each sample was injected into the electrospray transport solvent. The ESI spectrum was obtained in the multichannel acquisition mode, scanning from 500 to 1,800 *m/z* at a scan time of 7 s. The mass spectrometer is equipped with MassLynx and Transform software for data acquisition and spectrum handling.

N-terminal amino acid sequencing

The N-terminal amino acid residues of homogeneous recombinant MtSK were identified by automated Edman degradation sequencing method [28] using PPSQ 21A gas-phase sequencer (Shimadzu).

Oligomeric state determination

The oligomeric state of homogeneous MtSK was determined by size exclusion liquid chromatography on Superdex 200 (HR 10/30) column (GE Healthcare). The column was pre-equilibrated with 50 mM Tris-HCl pH 7.6 containing 200 mM NaCl at a flow rate of 0.4 mL min⁻¹ (4 °C), with UV detection at 280 nm. The calibration curve was constructed employing the following protein standards: ribonuclease A (13.7 kDa), quimotripsinogen (25 kDa), ovalbumine (43 kDa), albumine (67 kDa), aldolase (158 kDa), catalase (232 kDa), and ferritine (440 kDa). The elution volumes (V_e) of calibration proteins were used to calculate their corresponding partition coefficient (K_{av} , Eq. 1). Blue dextran was utilized for determination of the void volume (V_0). V_t is the total bead volume of the column. The K_{av} values for the standards were plotted versus the logarithm of their corresponding molecular masses. A volume of 100 μ L of recombinant protein was loaded on the gel filtration column to obtain V_e for MtSK.

$$K_{av} = \frac{V_e - V_0}{V_t - V_0} \quad \text{Eq. 1}$$

Steady-state kinetics

Recombinant *MtSK* enzyme activity was assayed in the the forward direction by coupling the ADP product to the pyruvate kinase (PK; EC 2.7.1.40) and lactate dehydrogenase (LDH; EC 1.1.1.27) reactions following the protocol described by Millar *et al.* [29]. Shikimate-dependent oxidation of NADH (nicotinamide adenine dinucleotide) was continuously monitored at 340 nm ($\epsilon = 6.22 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$). All reactions were carried out at 25 °C and initiated with addition of recombinant *MtSK* ($1 \mu\text{g mL}^{-1}$). The assay mixture contained 100 mM Tris–HCl buffer, pH 7.6, 100 mM KCl, 5 mM MgCl₂, 1.5 mM PEP, 0.2 mM NADH, 6 U mL⁻¹ PK, and 5 U mL⁻¹ LDH. Initial steady-state rates were calculated from the linear portion of the reaction curve under experimental conditions in which less than 5 % of substrate was consumed. True steady-state kinetics parameters were determined from initial velocity measurements at varying concentrations of SKH (37 - 4800 μM) at varied-fixed ATP concentrations (9 - 1200 μM).

Values of the steady-state kinetics parameters and their respective errors were obtained by fitting the data to the appropriate equations using the non-linear regression function of SigmaPlot 9.0 (SPSS, Inc). Hyperbolic saturation curves of initial rate data at single concentration of the fixed substrate and varying concentrations of the other were fitted to the Michaelis-Menten equation (Eq. 2) [30,31], in which v is the initial velocity, V is the apparent maximum initial velocity, A is the varying substrate concentration and K represents the apparent Michaelis-Menten constant.

$$v = \frac{VA}{K + A} \quad \text{Eq. 2}$$

The family of lines intersecting to the left of the y -axis in double-reciprocal plots was fitted to Eq. 3, which describes a mechanism involving ternary complex formation and a sequential substrate binding [30,31].

$$v = \frac{V_{\max} AB}{K_{ia} K_b + K_a B + K_b A + AB} \quad \text{Eq. 3}$$

For Eq. 3, v is the initial velocity (as for Eq. 2), V_{\max} is the true maximum initial velocity, A and B are the concentrations of the substrates, K_a and K_b are their respective Michaelis constants, and K_{ia} is the dissociation constant for enzyme-substrate A binary complex formation.

Equilibrium fluorescence spectroscopy

MtSK intrinsic protein fluorescence measurements were carried out to both determine the order of substrate/product addition/dissociation on/from the catalytic site and distinguish the enzyme kinetic mechanism. As *MtSK* has no tryptophan residues, changes in protein tyrosine fluorescence (the polypeptide chain of *MtSK* has 3 Tyr residues) upon ligand binding were monitored. Fluorescence measurements were carried out in a RF-5301 PC Spectrofluorophotometer (Shimadzu) at 25 °C. Excitation wavelength was 280 nm and emission spectra were collected from 300 to 500 nm. The maximum values of fluorescence intensity at 315 nm values were plotted as a function of increasing ligand concentration. Excitation and emission slits were 5 nm. As protein tyrosine typically has a low sensitivity (low molar absorption coefficient and low fluorescence quantum yield), *MtSK* concentration for binding experiments was 10 μ M.

Fluorescence titrations of binary complex formation were carried out by making microliter additions of the following compounds to 2 mL solution containing 10 μM *MtSK* in 100 mM Tris-HCl, 100 mM KCl, 5 mM MgCl_2 , pH 7.6: 120 mM SKH stock solution (10 – 1100 μM final concentration); 120 mM S3P stock solution (59.97-952.3 μM final concentration). Control experiments were performed in the same experimental conditions except that no substrate was added, and these values were subtracted from those obtained in the presence of substrate. However, owing to a large inner filter effect, ATP and ADP binding to free *MtSK* could not be determined by fluorescence spectroscopy.

Equilibrium fluorescence spectroscopy data were fitted to Eq. 4, in which F is the observed fluorescence, F_0 is the initial fluorescence, F_∞ is the maximum change in fluorescence at saturating ligand (L) concentration, and K_D represents the equilibrium dissociation constant for protein:ligand binary complex formation.

$$\frac{F_0 - F}{F_0 - F_\infty} = \frac{[L]}{K_D + [L]} \quad \text{Eq. 4}$$

Isothermal titration calorimetry (ITC)

ITC experiments were carried out using an iTC₂₀₀ Microcalorimeter (Microcal, Inc., Northampton, MA). The equipment's sample cell volume is 200 μL and syringe final volume is 39 μL . Calorimetric experiments were performed with either substrates (SKH and ATP) or products (S3P and ADP) at 298.15 K. The reference cell (200 μL) was loaded with water during all experiments and the sample cell (200 μL) was filled with *MtSK* at 100 μM concentration for ATP and ADP binding experiments, and at 130 μM for SKH and S3P binding experiments. The injection syringe (39 μL) was filled with

substrates or products at different concentrations: ATP and ADP at 6 mM, and SKH and S3P at 4.2 mM. Owing to the large enthalpy of ionization of Tris buffer [32] that we employed in steady-state kinetics and fluorescence spectroscopy, all ITC measurements were carried out in HEPES (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid) 50 mM, KCl 50 mM and MgCl₂ 5mM, pH 7.6. The binding reaction started with one injection of 0.5 μ L of ligand to prevent artifacts, followed by 17 injections of 2.26 μ L at intervals of 180 s, reaching a final volume 39 μ L with a stirring speed of 500 RPM. To evaluate the temperature dependence of the binding enthalpy of *MtSK*:SKH binary complex formation, the complex formation was investigated at several temperatures (273.15-313.15 K), in the same conditions as at 298.15 K (Eq. 5). Furthermore, binding experiments were carried out at pH 7.6 (298.15 K) in buffers with different enthalpies of ionization (ΔH_{ion}) (Pipes 2.68 kcal mol⁻¹; Hepes 4.88 kcal mol⁻¹; Imidazole 8.76 kcal mol⁻¹) [33] as a method to determine any proton exchange between the binary complex and buffer (N_{H^+}), the intrinsic enthalpy (ΔH_{int}) and a possible pK_a shift of an ionizable group in the binding pocket (Eq. 6 and Eq. 7). N_{H^+} represents the number of protons exchanged in the process of complex formation, and a negative value for N_{H^+} represents either the number of protons taken up by the buffer or released by the protein-ligand complex. For the Henderson-Hasselbalch equation (Eq.7), [HA] represents the concentration of acid and [A⁻] the concentration of its conjugate base. The heat variation was monitored inside the cell allowing determination of binding enthalpy of the process (ΔH) and the equilibrium association constant (K_a). All enthalpy values for binding reactions were exothermic. Control titrations were performed to subtract the heats of dilution and mixing for each experiment.

The Gibbs free energy (ΔG) of binding was calculated using the relationship described in Eq. 8, in which R is the gas constant (8.314 J K⁻¹ mol⁻¹; 1.987 cal K⁻¹ mol⁻¹), T is the temperature in Kelvin ($T = ^\circ\text{C} + 273.15$), and K_a is the association constant at

equilibrium. The entropy of binding (ΔS) can also be determined by this mathematical formula. Single set of sites model was utilized to determine the binding and thermodynamics constants. The initial value for n was fixed as 1 since *MtSK* is monomeric in solution, and estimates for K_a , and ΔH parameters were refined by standard Marquardt nonlinear regression method provided in the Origin 7 SR4 software.

$$\frac{\partial \Delta H}{\partial T} = \Delta C_p \quad \text{Eq. 5}$$

$$\Delta H = \Delta H_{\text{int}} + (N_{H^+}) \Delta H_{\text{ion}} \quad \text{Eq. 6}$$

$$pH = pK_a + \log \frac{[A^-]}{[HA]} \quad \text{Eq. 7}$$

$$\Delta G^0 = -RT \ln K_a = \Delta H^0 - T\Delta S^0 \quad \text{Eq. 8}$$

Molecular homology model building

To try to understand the protein conformational variation and non-covalent interactions upon SKH binding to *MtSK*, bioinformatics tools were used to reconstruct and analyze the structures. The missing residues in the structures of apo *MtSK* (PDB code 2IYT) and *MtSK* in complex with S3P and ADP (PDB code 2IYZ) were reconstructed using Modeller [34] and a total of 100 models were generated. The pose of SKH was based on that of S3P present in the crystal. Each model of the 100 complex models was minimized using the conjugate gradient algorithm (300 iterations) in Gromacs [35]. The polar (ΔASA_{pol}) and non-polar ($\Delta ASA_{\text{non-pol}}$) solvent accessible surface areas (ASA) were calculated using an analytical method based on Voronoi surfaces [36]. To account for the

dynamic nature of protein structures, ASA values were calculated for each individual complex and their average values used in the analysis.

Results and Discussion

Recombinant MtSK protein purification

Recombinant *MtSK* was purified to homogeneity using a three-step protein purification protocol comprising a crude extract precipitation, a hydrophobic chromatographic step (Phenyl Sepharose) followed by a gel filtration column (Sephacryl S-100) (**Fig. 2**). The protein precipitation of the crude extract with MgCl_2 at a final concentration of 10 mM was efficient at precipitating *MtSK* whereas a number of contaminants remained in the supernatant. It has been pointed out that direct ion-macromolecule interactions as well as interactions with water molecules in the first hydration shell of macromolecules appear to play a central role to Hofmeister effects [37]. The Hofmeister series ranks the relative influence of ions on the physical behavior of a wide variety of aqueous processes ranging from colloidal assembly to protein folding. Usually, the specific ion effects of the Hofmeister series are more pronounced for anions than for cations [37]. The Cl^- anion is situated in the borderline between kosmotropes (“water structure makers”, strongly hydrated, stabilizing and salting-out effects on proteins) and chaotropes (“water structure breakers”, destabilize folded proteins and have salting-in effects on proteins) species. The Mg^{2+} ion has chaotropic (salting-in) effect. It is thus somewhat puzzling the salting-out effect of 10 mM MgCl_2 on *MtSK*. However, it has recently been pointed out that the transport number of Mg^{2+} cation is higher than that for the other common biological cations, and the solvent exchange rate is over 3 orders of

magnitude less than that for other common cations [38]. It would thus imply that Mg^{2+} cation would have a significant but largely unstudied effect on ordering of solvent and molecules in solution [38]. Notwithstanding, it is not warranted to advance any definite explanation as regards the $MgCl_2$ salting-out effect on *MtSK*. This protein precipitation step was followed by two chromatographic steps, namely, a hydrophobic followed by a size-exclusion column, yielding approximately 20 mg of functional homogenous *MtSK* per 1.5 L of cell culture. The homogeneous recombinant *MtSK* was stored in 85 % $(NH_4)_2SO_4$ at 4°C with no loss of activity.

Electrospray ionization mass spectrometry (ESI-MS) analysis

A value of 18,451 Da for the subunit molecular mass of recombinant *MtSK* protein was determined by ESI-MS. This result is consistent with post-translational removal of N-terminal methionine residue (131.2 Da) from the full-length gene product (predicted mass, 18,583 Da). The ESI-MS result also revealed no peak at the expected mass of both *aroK*-encoded Shikimate Kinase I (19,526 Da) and *aroL*-encoded Shikimate Kinase II (18,998 Da) from *E. coli* SK [39], thus providing support for the identity of purified recombinant protein.

N-terminal amino acid sequencing

The first 8 N-terminal amino acid residues of recombinant *MtSK* were identified as APKAVLGL by the Edman degradation sequencing method. This result unambiguously

identifies the purified protein as *MtSK*, since the N-terminal amino acid sequence of *aroK*-encoded Shikimate Kinase I and *aroL*-encoded Shikimate Kinase II from *E. coli* are, respectively, MAEKRNIFLV and MTQPLFLIGP. The Edman degradation result also confirms removal of the N-terminal methionine residue, and is in agreement with no observation of N-terminal methionine in the crystal structure of *MtSK*:MgADP:SKH ternary complex [19]. The excision of N-terminal methionine is a common type of post-translational modification process that occurs in protein synthesized in the cytoplasm of prokaryotic cells. The cleavage of the initiator methionine is usually directed by the penultimate amino acid residues with the smallest side chain radii of gyration (Gly, Ala, Ser, Thr, Pro, Val, and Cys) [40]. Removal of N-terminal methionine from recombinant *MtSK* polypeptide chain conforms to this rule since alanine is the penultimate amino acid residue.

Oligomeric state determination

A value of 20.7 ± 0.5 kDa for the molecular mass of homogeneous recombinant *MtSK* was estimated by gel filtration chromatography (data not shown). This result demonstrates that *MtSK* is a monomer in solution, since ESI-MS analysis suggested a value of 18,451 Da for the subunit molecular mass of the recombinant protein.

Steady-state kinetics

Hyperbolic initial velocity as a function of substrate concentration (either ATP or SKH) was plotted as a linear function of reciprocal of initial velocity against the reciprocal of substrate concentration (double-reciprocal or Lineweaver-Burk plot). These data allow both determination of true steady-state kinetic parameters and a proposal for *MtSK*

enzyme mechanism. The double-reciprocal plots showed a family of lines intersecting to the left of the y -axis (**Fig.3**), which is consistent with ternary complex formation and a sequential mechanism. This pattern of lines rules out ping-pong (parallel lines), steady-state random (that gives non-linear reciprocal plots), and rapid-equilibrium ordered (one of the family of lines should cross at a single value on the y -axis) mechanisms. However, the double-reciprocal plots alone cannot distinguish between rapid-equilibrium random and steady-state compulsory ordered bi bi mechanisms. The double-reciprocal data were fitted to the equation for a sequential initial velocity pattern (Eq. 3), yielding the following values for the true steady-state kinetic parameters (Table 1): $k_{cat} = 60 (\pm 8) \text{ s}^{-1}$, $K_{MgATP} = 112 (\pm 4) \mu\text{M}$, $K_{SKH} = 650 (\pm 28) \mu\text{M}$, $k_{cat}/K_{MgATP} = 5.4 (\pm 0.7) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$, and $k_{cat}/K_{SKH} = 0.9 (\pm 0.1) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$. *E. coli* has two Shikimate Kinase enzymes: *aroK*-encoded SK I and *aroL*-encoded SK II [41]. The K_{SKH} value for *E. coli* SK I (20 mM) is larger than the value for *E. coli* SK II (200 μM) (**Table 1**). Although the complete sequencing of *M. tuberculosis* H37Rv genome has identified by sequence homology the presence of *aroK*-encoded SK I [42], the kinetic data presented here and elsewhere [43] show that *MtSK* would more appropriately be described as an *aroL*-encoded type II enzyme. In addition, although the steady-state kinetic parameters are in good agreement with ones previously reported [43], no description of *MtSK* enzyme mechanism was presented, indicating a need of a more complete enzymatic study, as described here. To distinguish between random and compulsory ordered bi bi mechanisms, substrate(s) and product(s) binding experiments were carried out as described below.

Equilibrium fluorescence spectroscopy

In equilibrium binary complex formation experiments, there was a quench in the intrinsic *MtSK* protein fluorescence upon binding of SKH, however no fluorescence variation was observed due to S3P presence. Titration of *MtSK* with SKH was hyperbolic (**Fig.4**), and fitting the data to Eq. 4 yielded a value of 113 (± 4) μM for the equilibrium dissociation constant of SKH (K_D). No change in protein fluorescence could be observed for S3P binding to free *MtSK* (data not shown). However, it cannot be assumed that no *MtSK*:S3P binary complex was formed because S3P binding to free enzyme may result in no change in protein fluorescence. In addition, as previously mentioned, ATP and ADP binding to *MtSK* could not be assessed by fluorescence spectroscopy due to large inner filter effects. Accordingly, ITC experiments were carried out.

Isothermal titration calorimetry (ITC)

ITC measurements were carried out to both determine the order, if any, of addition of substrate and the order of product release to yield free enzyme. In agreement with fluorescence spectroscopy results, no binding of S3P to free enzyme could be detected by ITC measurements (data not shown). On the other hand, ITC measurements showed binding of SKH, Mg^{2+} ATP and Mg^{2+} ADP to free *MtSK* enzyme (**Fig.5, Table 2**). These results support a mechanism in which binding of substrates (SKH and ATP) to *MtSK* is random, and S3P product release is followed by ADP dissociation to yield free enzyme. The value for the SKH equilibrium dissociation constant determined at 298.15 K by fluorescence spectroscopy (113 μM) is in good agreement with the value determined from ITC data (181 μM) at the same temperature. As the double-reciprocal plots of initial

velocity measurements could not distinguish between rapid-equilibrium random and steady-state compulsory ordered bi bi mechanisms, fluorescence spectroscopy and ITC results indicate that the bi bi mechanism of *MtSK* is rapid-equilibrium random order of substrate addition. Based on a series of crystal structures, it has been proposed that substrate binding to *MtSK* is random [23], in agreement with the results presented here. However, whether an enzyme mechanism is rapid equilibrium or steady state cannot be identified by crystal structure determinations. In addition, crystal structure analysis suggested that ADP product release is followed by S3P to generate free enzyme [23]. Here we demonstrate that S3P product is released first, followed by dissociation of ADP from *MtSK*:ADP binary complex to generate free enzyme for the next round of catalysis.

The ITC results showed significant heat changes upon ligand (SKH, ATP, or ADP) binding to free *MtSK* enzyme, thereby providing thermodynamic signatures of non-covalent interactions to each binding process. Observed enthalpies arise largely as a result of changes in interatomic interactions (e.g., hydrogen bonds and/or van der Waals interactions), in which the sign indicates whether there is a net favourable (negative ΔH) or unfavourable (positive ΔH) redistribution of the network of interactions between the reacting species (including solvent) [44]. Hydrophobic interactions are related to the relative degrees of disorder in the free and bound systems and thus these interactions are reflected in the entropy change. The release of “bound” water molecules from a surface to the bulk solvent is usually a source of favourable entropy (positive ΔS). A reduction in conformational states in either ligand or protein upon binary complex formation is entropically unfavourable (negative ΔS) [44].

The ITC data for Mg^{2+} ADP binding to *MtSK* suggest that it is accompanied by a favourable redistribution of H-bonds and/or van der Waals interactions, and a large entropically unfavorable contribution, resulting in a large value for the equilibrium

dissociation constant (**Table 2**). It is thus tempting to suggest that large *MtSK* protein conformational changes occurring upon dissociation of $Mg^{2+}ADP$ from *MtSK*: $Mg^{2+}ADP$ binary complex would regenerate free enzyme in a conformation that allows binding of substrate(s) to start a new cycle of catalysis. In addition, the large K_D value for ADP may avoid *MtSK*: $Mg^{2+}ADP$:SKH dead-end ternary complex formation, which would lock the enzyme active site in an inactive form. The ITC data for $Mg^{2+}ATP$ binding to *MtSK* indicate that the molecular recognition process is accompanied by favourable redistribution of H-bonds and/or van der Waals interactions, and unfavourable entropic contribution (**Table 2**). The latter may reflect protein conformational changes upon $Mg^{2+}ATP$ binding. As pointed out above, *MtSK* belongs to the family of NMP kinases, which are composed of CORE, LID and NMP-binding (SKH-binding or SB) domains. The LID domain closes the active site and has residues that are essential for ATP binding [19-23]. Moreover, NMP kinases undergo large conformational changes during catalysis [24]. It should be pointed out that a fourth domain has been proposed to be present in *MtSK* structure, namely, the RC domain [23]. Interestingly, the dissociation constant value for binding of ATP (196 μM) is smaller than for ADP (562 μM). It may be accounted for by the direct interaction between the γ -phosphate of ATP and either Arg117 residue observed in the crystal structure of *MtSK*:ATP binary complex or Lys15 that is part of the P-loop [23]. The unfavourable entropic contributions upon ATP and ADP binding to free *MtSK* enzyme can thus be accounted for by protein conformational changes. The NMP-binding (or SB) domain of *MtSK* functions to recognize and bind SKH [19-23]. The SKH substrate binding to free *MtSK* is associated with favourable H-bonds and/or van der Waals interactions and a positive entropic contribution (**Table 2**). The latter may reflect release of “bound” water molecules either from substrate or from *MtSK* active site to solvent. Since SKH is a hydrophilic molecule, with a logP of -2.22 and a logD at pH 7.4 of -5.1 the release of

water molecules from the complex to the bulk is among a likely contribution to the favorable entropy of binding [45]. This favorable entropic contribution should however compensate for the unfavorable entropic contribution due to conformational changes known to occur upon SKH binding to *MtSK* [19, 21-23]. The equilibrium constant for the intramolecular hydrolysis of bound ATP to bound ADP and phosphate at enzyme active sites is considerably larger than the equilibrium constant for ATP hydrolysis in solution [46]. The ITC data on SKH binding may indicate exclusion of water molecules from *MtSK* active site to minimize ATP hydrolysis, in agreement with previous proposals [19]. Taken together, the ITC data may be reporting on protein conformational changes upon ATP or ADP binding, and on exclusion of water molecules from *MtSK* active site upon SKH binding. These conclusions are in agreement with structural data on *MtSK* that showed large rotational movement of the nucleotide binding domain upon ADP and ATP binding, bringing it closer to the SKH binding domain [23]. However, the ITC data on SKH at 298.15 K suggest that the unfavorable entropy due to rotational movements of the ESB domain and LID closure upon substrate binding to *MtSK* [23] is likely to be cancelled out by the release of water molecules to bulk solvent.

The temperature dependence of thermodynamics parameters can point to the hydrophobic properties of the SKH interaction with *MtSK* [45]. Changes in constant pressure heat capacity (ΔC_p) on going from free to bound states have been used to correlate complex formation with burial of surface area [44, 45]. The data presented in **Fig.6A** shows a graphical representation of observed ΔG , ΔH and $-T\Delta S$ versus temperature for experiments performed at pH 7.6 in standard buffer (Hepes 50mM, KCl 50mM and $MgCl_2$ 5mM). A value of $-320 (\pm 16)$ cal mol⁻¹ K⁻¹ for ΔC_p (Eq. 5) of substrate binding was derived from the slope of the linear curve describing the changes in ΔH values as a function of increasing temperature (**Fig.6A**). Previous works showed that the

nature of a negative ΔC_p can be derived from difference in polar and non-polar surface areas exposed to the solvent [47, 48]. Since ΔC_p is strongly correlated with polar and non-polar surface exposed to the solvent [49], the variation of the surfaces were analyzed subtracting the solvent accessible surface areas (ASA) of free forms of SKH and *Mt*SK from *Mt*SK:SKH binary complex. Values of 440 Å² and 1262 Å² were estimated for, respectively, ΔASA_{pol} and $\Delta ASA_{\text{non-pol}}$. These estimates suggest that desolvation of non-polar groups upon binary complex formation makes a more pronounced contribution to ΔC_p (negative) as compared to desolvation of polar groups (positive). This phenomenon can be addressed by the classical explanation that hydrophobic effect is due to the properties of solvent water in repelling non-polar molecules and groups [50]. Upon binary complex formation, the $\Delta ASA_{\text{non-pol}}$ value indicates that there is a decrease in the number of non-polar groups exposed to the solvent. The negative value for ΔC_p could indicate a reduction in the number of hydration shells of non-polar groups, and ensuing decrease in entropy as temperature increases (positive value for $-T\Delta S$) and constant $\Delta G/\Delta T$ (**Fig.6A**). The nature of this interaction is temperature dependent [50], which is endothermic at low temperatures and exothermic at higher temperatures, as appears to be borne out by the results presented in **Fig.6A**. A decrease in vibrational freedom upon binary complex formation and ensuing decrease in the energy of fluctuation between two states may also be invoked to explain the negative value for ΔC_p . Notwithstanding, there are a number of contributing factors to ΔC_p values, including hydrogen bonding, electrostatics, protein conformational entropy and changes in equilibrium [49] that were not taken into account in our data analysis. The thermodynamic data in the temperature range studied show enthalpy-entropy compensation, resulting in temperature-independent ΔG values.

Gurney defined the ΔS as the sum of two components, the unitary entropy (ΔS_U) and the cratic entropy (ΔS_C) [51]. As pointed out by Irudayam and Henchman [52], the

ΔS_C is a “controversial term whose interpretation and inclusion has been the subject of much debate”, since, after 59 years later Gurney paid attention to this term, a consensus about this theory has not been found. Sturtevant in 1977 [49] considered the ΔS_C in the formulation of his empirical method. A value of $+7.9826 \text{ cal K}^{-1} \text{ mol}^{-1}$ [53] for the cratic contribution was used to correct the ΔS values found in this work to give ΔS_U .

Hydrophobic and vibrational components of thermodynamic parameters were achieved utilizing the empirical method developed by Sturtevant [49], in which the ΔS , ΔH and ΔC_p are deconvoluted in vibrational and hydrophobic contributions (**Table 3**). These results show that there is a strong hydrophobic contribution upon *MtSK*:SKH binary complex formation, suggesting a decrease in the contact of the solvent with the apolar groups. In addition, there is an increase in magnitude of the vibrational contribution, which, as suggested by Sturtevant [49], may be ascribed to conversion of soft internal vibrational modes to stiffer modes upon ligand (SKH) binding. The crystal structure of *MtSK*:SKH binary complex indicated that there appears to be a continuum of conformations, and that one of them showed no closure of the LID domain upon SKH binding [23], which would be consistent with no conformational changes upon SKH binding that would be entropically unfavorable and water release as the main contribution to the favorable entropy (positive ΔS). In addition, the results presented here (**Tables 2 and 3**) indicate that the unfavorable entropy due to rotational movements of the ESB domain and LID closure following SKH binding to *MtSK* [23] is likely to be cancelled out by hydrophobic and vibrational contributions to binary complex formation.

Ligand binding processes can be accompanied by protein and/or substrate protonation/deprotonation. Consequently, the ΔH observed depends not only on the intrinsic enthalpy but also the enthalpy related to an ionization event occurring on complex formation, as described in Eq. 6. Shikimate binding processes were thus

evaluated in buffers with different enthalpies of ionization and the results are presented in **Fig. 6B** and **Table 2**. The results show a linear decrease to values of $N_{H^+} = -0.47 \pm 0.01$ and a ΔH_{int} of $-3.2 \text{ kcal mol}^{-1}$ (Y-axis intercept corresponding to $\Delta H_{\text{ion}} = 0$), indicating release of protons from the *MtSK*:SKH binary complex to the bulk solvent. In other words, there are less protons associated with the binary complex than in the free interacting molecules, i.e. there is no sequestering of protons from bulk solution in the protein structure upon SKH binding to *MtSK*. To try to address the possible source of proton released into solution, the pK_a values of amino acid side chains in the catalytic site were analyzed based on structural information [23]. Employing the pK_a values of 3.9, 4.47 and 12.5 for, respectively, Asp (β -COOH), SKH (1-COOH) and Arg (δ -guanidino) amino acid residues in solution, the change in the protonated fraction of a reactant species at a fixed pH value can be inferred by the Henderson-Hasselbalch equation (**Eq. 7**). This analysis permits to predict that there is a proportion of $10^{-4.9}$ of protonated Arg side chain (either Arg58 or Arg136) at pH 7.6. SKH and Asp34 at pH 7.6 show a proportion of, respectively, $10^{+3.13}$ and $10^{+3.7}$ of deprotonated (conjugate bases) in relation to protonated forms. Hence, the δ -guanidinium groups of Arg side chains located in the catalytic site (Arg58 and Arg136) are likely the proton donors to bulk solvent, which could account for the release of protons from *MtSK*:SKH binary complex into solution. The latter will convert the salt bridge between the Arg side chain and the carboxyl group of SKH into hydrogen bonds between the reacting species. In agreement with this proposal, these interactions have been shown for SKH in complex with *MtSK* [19,21,22,23,43,]. Interestingly, the K_D value for SKH in imidazole buffer (Table 2) appears to be larger as compared to K_D values in Hepes and Pipes. To assess whether or not imidazole has any inhibitory effect on *MtSK* activity, measurements of enzyme velocity in the presence of this chemical compound were carried out. No enzyme inhibition could be observed in assay mixture

containing 50 mM of imidazole (9.5 U mL^{-1}) as compared to assay mixture in the absence of imidazole (9.2 U mL^{-1}). Interestingly, SKH has been shown to bind to *MtSK* with half occupancy [23]. It is thus tempting to suggest that the value of -0.47 for N_{H^+} may reflect this structural feature of *MtSK*:SKH binary complex formation.

It has been shown for *aroL*-encoded SK from *Erwinia chrysanthemi* (*EcSK*) that the K_M for ATP ($620 \text{ }\mu\text{M}$) is approximately four times lower than its K_D value (2.6 mM) [54]. These results prompted the proposal that the conformational changes in *EcSK* associated with binding of the first substrate leads to an increase in the affinity for the second substrate. However, based on the results for Mg^{2+}ATP , it does not appear to hold for *MtSK* since the K_M value ($112 \text{ }\mu\text{M}$) is in the same concentration range of K_D determined from ITC measurements ($196 \text{ }\mu\text{M}$). It has been put forward that the K_M value for a substrate in rapid-equilibrium random-order mechanisms is equal to the equilibrium dissociation constant for dissociation of the substrate from the ternary complex [55]. The K_M value for SKH (**Table 1**, $650 \text{ }\mu\text{M}$) is approximately 3.6-fold larger than its K_D value (**Table 2**, $181 \text{ }\mu\text{M}$). These results suggest a positive free energy coupling ($\Delta G_{\text{coop}} = 3.2 \text{ kJ mol}^{-1}$) for SKH binding to *MtSK*: Mg^{2+}ATP . There thus appears to be a negative cooperativity ($\Delta G_{\text{coop}} > 0$) [56] in energy coupling of Mg^{2+}ATP binding to *MtSK* on SKH binding to the binary complex and ensuing ternary complex formation. This finding is somewhat puzzling because one would expect that Mg^{2+}ATP binding to *MtSK* should result in increased affinity for SKH. However, this proposal should be taken with caution as there may be additional step(s) that should be added to the simple mechanism depicted in **Fig. 7**. The energy conservation law dictates that the product of K_D and K_M with SKH binding first should give a value equal to (or approximately the same) the product of K_D and K_M with Mg^{2+}ATP binding first. There is, however, a 6-fold difference for the product of dissociation constants between the routes from the apo enzyme to ternary

complex formation. This discrepancy could tentatively be ascribed to either an additional step that could not be detected by the experimental approaches employed or to result from having treated the K_M values as “true” (microscopic) dissociation constants. Interestingly, no direct interaction between SKH and the LID domain of *MtSK* was seen when SKH binds as the second ligand to the nucleotide-bound enzyme [23]. It is tempting to suggest that these reduced interactions may account for the larger K_M value as compared to K_D for SKH.

Summary

Steady-state kinetics, fluorescence spectroscopy and isothermal titration calorimetry data showed that the enzyme mechanism of monomeric *MtSK* is rapid-equilibrium random order of substrate addition, and ordered product release with S3P being released first followed by ADP dissociation from the binary complex to regenerate free enzyme (**Fig.7**). The thermodynamic signatures of non-covalent interactions obtained from ITC data upon substrate(s)/product(s) binding to *MtSK* demonstrated conformational changes following nucleotide binding and release of “bound” water molecules from SKH and/or *MtSK* active site to bulk solvent. Results of the dependence of enthalpy on both temperature and buffer ionization upon *MtSK*:SKH binary complex formation suggested a large hydrophobic contribution to substrate binding and indicated an important role of Arg58 and Arg136 side chains in SKH binding. Interestingly, although the genome sequencing of *M. tuberculosis* H37Rv strain has identified *MtSK* as an *aroK*-encoded enzyme (SK I) [42], which has a large value for the Michaelis-Menten constant of SKH, the measurements of true steady-state kinetic parameters presented here and elsewhere [43] show that *MtSK* would more appropriately be described as an *aroL*-encoded type II

enzyme (SK II). Incidentally, it has recently been pointed out that understanding the mode of action of an enzyme can be used to inform functional annotation of newly determined sequences and structures, to select appropriate enzyme scaffolds for engineering new functions, and to refine definitions in the current EC classifications [57].

The currently available repertoire of antimycobacterial agents reveals only a handful of comprehensively validated targets, namely RNA polymerase, DNA gyrase, NADH-dependent enoyl-ACP reductase and ATP synthase [58]. The complete genome sequencing of *M. tuberculosis* H37Rv strain has accelerated the study and validation of molecular targets aiming at the rational design of anti-TB drugs [42]. The target-based rational design of new agents with anti-TB activity includes functional and structural efforts. Accordingly, mechanistic analysis should be included in enzyme-targeted drug programs aiming at the rational design of potent enzyme inhibitors. Moreover, ITC has been used as an important technique for the direct determination of thermodynamic and kinetic parameters of enzymatic reactions [59]. As mentioned above, the recognition of the limitations of high-throughput screening approaches in the discovery of candidate drugs has renewed interest in ITC data in the rational design of chemotherapeutic agents [6]. Moreover, understanding the mode of action of *MtSK* will inform us on how to better design inhibitors targeting this enzyme with potential therapeutic application in TB chemotherapy. It is thus hoped that the results here described may be useful to the rational design of anti-TB agents and that they may contribute to our understanding of the biology of *M. tuberculosis*.

References

- [1]. World Health Organization (2010) Global Tuberculosis Control 2010. Geneva: WHO Press.
- [2]. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO Press
- [3]. Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, et al. (2009) Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. *Eur Respir J* 34: 1202-1203.
- [4]. Robertson JG (2005) Mechanistic basis of enzyme-targeted drugs. *Biochemistry* 44: 5561-5571.
- [5]. Robertson JG (2007) Enzymes as a special class of therapeutic target: clinical drugs and modes of action. *Curr Opin Struct Biol* 17: 674-679.
- [6]. Ladbury JE, Klebe GK and Freire E (2010) Adding calorimetric data to decision making in lead discovery: a hot tip. *Nat Rev Drug Discov* 9: 23-27.
- [7]. Ducati RG, Basso LA, Santos DS (2007) Mycobacterial shikimate pathway enzymes as targets for drug design. *Curr Drug Targets* 8: 423-435.
- [8]. Bentley R (1990) The shikimate pathway: a metabolic tree with many branches. *Crit Rev Biochem Mol Biol* 25: 307–384.
- [9]. Campbell SA, Richards TA, Mui EJ, Samuel BU, Coggins JR, et al. (2004) A complete shikimate pathway in *Toxoplasma gondii*: an ancient eukaryotic innovation. *Int J Parasitol* 34: 5–13.
- [10]. Roberts CW, Roberts F, Lyons RE, Kirisits MJ, Mui EJ, et al. (2002) The shikimate pathway and its branches in apicomplexan parasites. *J Infect Dis* 185: S25–S36.

- [11]. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, et al. (1998) Evidence for the shikimate pathway in apicomplexan parasites. *Nature* 393: 801–805.
- [12]. Keeling PJ, Palmer JD, Donald RG, Roos DS, Waller RF, et al. (1999) Shikimate pathway in apicomplexan parasites. *Nature* 397: 219–220.
- [13]. McConkey GA (1999) Targeting the shikimate pathway in the malaria parasite *Plasmodium falciparum*. *Antimicrob Agents Chemother* 43: 175–177.
- [14]. McConkey GA, Pinney JW, Westhead DR, Plueckhahn K, Fitzpatrick TB, et al. (2004) Annotating the *Plasmodium* genome and the enigma of the shikimate pathway, *Trends Parasitol* 20: 60–65.
- [15]. McFadden GI, Reith ME, Munholland J., Lang-Unnasch N (1996) Plastid in human parasites. *Nature* 381: 381-482.
- [16]. Starcevic A, Akthar S, Dunlap WC, Shick JM, Hranueli D, et al. (2008) Enzymes of the shikimic acid pathway encoded in the genome of a basal metazoan, *Nematostella vectensis*, have microbial origins, *Proc Natl Acad Sci USA* 105: 2533-2537.
- [17]. Parish T, Stoker NG (2002) The common aromatic amino acid biosynthesis pathway is essential in *Mycobacterium tuberculosis*, *Microbiology* 148: 3069–3077.
- [18]. Oliveira JS, Pinto CA, Basso LA, Santos DS (2001) Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from *Mycobacterium tuberculosis*. *Protein Expr Purif* 22: 430–435.

- [19]. Pereira JH, Oliveira JS, Canduri F, Dias MV, Palma MS, et al. (2004) Structure of shikimate kinase from *Mycobacterium tuberculosis* reveals the binding of shikimic acid. *Acta Crystallogr D Biol Crystallogr* 60: 2310-2319.
- [20]. Dias M.V, Faím LM, Vasconcelos IB, Oliveira JS, Basso LA, et [al.](#) (2007) Effects of magnesium and chloride ions and shikimate on the structure of shikimate kinase from *Mycobacterium tuberculosis*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 63: 63: 1-6.
- [21]. Dhaliwal B, Nichols CE, Ren J, Lockyer M, Charles I, et al. (2004) Crystallographic studies of shikimate binding and induced conformational changes in *Mycobacterium tuberculosis* shikimate kinase. *FEBS Lett* 574: 49-54.
- [22]. Gan J, Gu Y, Li Y, Yan H, Ji X (2006) Crystal structure of *Mycobacterium tuberculosis* shikimate kinase in complex with shikimic acid and an ATP analogue. *Biochemistry* 45: 8539-8545.
- [23]. Hartmann MD, Bourenkov GP, Oberschall A, Strizhov N, Bartunik HD (2006) Mechanism of phosphate transfer catalyzed by shikimate kinase from *Mycobacterium tuberculosis*. *J Mol Biol* 364: 411-423.
- [24]. Vonrhein C, Schlauderer GJ, Schulz GE (1995) Movie of the structural changes during a catalytic cycle of nucleoside monophosphate kinases. *Structure* 3: 483-490.
- [25]. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- [26]. Bradford MM, McRorie RA, Williams WL (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248–254.

- [27]. Chassaigne H (1998) Characterization of horse kidney metallothionein isoforms by electrospray MS and reversed-phase HPLC-electrospray MS. *Analyst* 123 : 2125–2130.
- [28]. Edman P, Begg G (1967) A protein sequenator. *Eur J Biochem* 1: 80-91.
- [29]. Millar G, Lewendon A, Hunter MG, Coggins JR (1986) The cloning and expression of the *aroL* gene from *Escherichia coli* K12. Purification and complete amino acid sequence of shikimate kinase II. the *aroL*-gene product, *Biochem J* 237: 427–437.
- [30]. Segel IH (1993) *Enzyme kinetics - Behavior analysis of rapid equilibrium and steady-state enzyme systems*. Wiley-Interscience Publication, John Wiley & Sons, Inc, New York, USA.
- [31]. Cook PF, Cleland WW (2007) Enzyme assays. In: *Enzyme kinetics and mechanism*. Garland Science. pp. 19-34.
- [32]. Fukada H, Takahashi K (1998) Enthalpy and heat capacity changes for the proton dissociation of various buffer components in 0.1 M potassium chloride. *Proteins* 33: 159-166.
- [33]. Goldberg RN, Kishore N, Lennen RM (2002) Thermodynamic quantities for the ionization reactions of buffers. *J Phys Chem Ref Data* 31: 231-370.
- [34]. Eswar N, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D (2006) Comparative protein structure modeling with MODELLER. *Curr Protoc Bioinformatics Supplement* 15: 5.6.1-5.6.30.
- [35]. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. *J Chem Theory Comput* 4: 435-447.

- [36]. McConkey BJ, Sobolev V, Edelman M (2002) Quantification of protein surfaces, volumes and atom-atom contacts using a constrained Voronoi procedure. *Bioinformatics* 18: 1365-1373.
- [37]. Zhang Y, Cremer PS (2006) Interactions between macromolecules and ions: the Hofmeister series. *Curr Opin Chem Biol* 10: 658-663.
- [38]. Maguire ME, Cowan JA (2002) Magnesium chemistry and biochemistry. *BioMetals* 15: 203-210.
- [39]. Whipp MJ, Pittard AJ (1995) A reassessment of the relationship between *aroK*- and *aroL*-encoded shikimate kinase enzymes of *Escherichia coli*. *J Bacteriol* 177: 1627-1629.
- [40]. Hirel PH, Schmitter MJ, Dessen P, Fayat G, Blanquet S (1989) Extent of N-terminal methionine excision from *Escherichia coli* proteins is governed by the side-chain length of the penultimate amino acid. *Proc Natl Acad Sci USA* 86: 8247-8251.
- [41]. Pittard AJ (1996). In: Neidhardt FC, editors. *Escherichia coli* and *Salmonella*: Cellular and Molecular Biology. ASM Press.
- [42]. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393: 537-544.
- [43]. Gu Y, Reshetnikova L, Li Y, Wu Y, Yan H, et al. (2002) Crystal structure of shikimate kinase from *Mycobacterium tuberculosis* reveals the dynamic role of the LID domain in catalysis. *J Mol Biol* 319: 779-789.
- [44]. O'Brien R, Haq I (2004). In Ladbury JE, Doyle ML, editors. *Biocalorimetry 2: Applications of calorimetry in the biological sciences*. John Wiley and Sons.

- [45]. Cooper A (2005) Heat capacity effects in protein folding and ligand binding: a re-evaluation of the role of water in biomolecular thermodynamics. *Biophys Chem* 115: 89-97.
- [46]. Jencks WP (1975) *Catalysis in chemistry and enzymology*. Dover Publications, Inc., New York.
- [47]. Edsall JT (1935) Apparent molal heat capacities of amino acids and other organic compounds. *J Am Chem Soc* 57: 1506-1507.
- [48]. Gill SJ, Wadso I (1976) An equation of state describing hydrophobic interactions. *Proc Natl Acad Sci USA* 73: 2955-2958.
- [49]. Sturtevant JM (1977) Heat capacity and entropy changes in processes involving proteins. *Proc Natl Acad Sci USA* 74: 2236-2240.
- [50]. Kauzmann W (1959) Some factors in the interpretation of protein denaturation. *Adv Prot Chem* 14: 1-63.
- [51]. Gurney RW (1953) *Ionic processes in solution*. McGraw-Hill Book Company, Inc, New York, Toronto, London.
- [52]. Irudayam SJ, Henschman RH (2009) Entropic cost of protein-ligand binding and its dependence on the entropy in solution. *J Phys Chem B* 113: 5871-5884.
- [53]. Takahashi K, Fukada H (1985) Calorimetric studies of the binding of *Streptomyces* subtilisin inhibitor to subtilisin of *Bacillus subtilis* strain N'. *Biochemistry* 24: 297-300.
- [54]. Krell T, Maclean J, Boam DJ, Cooper A, Resmini M, et al. (2001) Biochemical and X-ray crystallographic studies on shikimate kinase: The important structural role of the P-loop lysine. *Protein Sci* 10: 1137–1149.
- [55]. Engel PC (1977) *Enzyme kinetics*. John Wiley & Sons, Inc, New York.

- [56]. Weber G (1975) Energetics of ligand binding to proteins. *Adv Protein Chem* 29: 1-83.
- [57]. Almonacid DE, Yera ER, Mitchell JBO, Babbitt PC (2010) Quantitative comparison of catalytic mechanisms and overall reactions in convergently evolved enzymes: implications for classification of enzyme function. *PLoS Comput Biol* 6(3) e10000700.
- [58]. Balganesh TS, Alzari PM, Cole ST (2008) Rising standards for tuberculosis drug development. *Trends Pharmacol Sci* 29: 576-581.
- [59]. Bianconi ML (2007) Calorimetry of enzyme-catalyzed reactions. *Biophys Chem* 126: 59-64.

Figure legends

Fig.1. Shikimate Kinase catalyzed phosphoryl transfer from ATP to C3 hydroxyl group of shikimate (SKH), yielding shikimate 3-phosphate (S3P) and ADP.

Fig.2. 12% SDS-PAGE analysis of pooled fractions of MtSK for each purification step. Lane 1, Protein Molecular Weight Marker (Fermentas); lane 2, soluble *E. coli* BL21 (DE3) [pET-23a(+):aroK] extract; lane 3, Soluble proteins after 10 mM MgCl₂ precipitation step; lane 4, Phenyl Sepharose 16/10; and lane 5, Sephacryl S-100 HR.

Fig.3. Double-reciprocal plots for steady-state kinetics of MtSK using either ATP (**A**) or SKH (**B**) as the variable substrate. Each curve represents varied-fixed levels of the co-substrate, ranging from 37 to 4800 μM for SKH and from 9 to 1200 μM to ATP.

Fig.4. Fluorescence spectroscopy of the equilibrium binding of SKH to MtSK, measuring the quench in intrinsic protein fluorescence upon ligand binding and plotting the relative fluorescence change as a function of SKH concentration.

Fig.5. Isothermal titration calorimetry (ITC) analysis of either SKH (**A**), Mg²⁺ATP (**B**), or Mg²⁺ADP (**C**) binding to MtSK. The top graphs show raw data of the heat pulses resulting from titration of MtSK (100 μM for ATP and ADP, and 130 μM for SKH and S3P) in the calorimetric cell with one injection of 0.5 μL of ligand followed by 17 injections of 2.26 μL injection. The injection syringe (39 μL) contained either ATP or ADP at 6mM, or SKH and S3P at 4.2 mM. The bottom graphs show the integrated heat pulses, normalized per mol

of injectant as a function of the molar ratio (ligand/*MtSK* concentration). These binding curves were best fitted to a single set of sites model equation.

Fig.6. *MtSK*:SKH thermodynamic binding parameters as a function of temperature (A) and binding enthalpy as a function of buffer ionization enthalpy at pH 7.6 (B). Figure 7A shows the ΔH (filled circles), $-T\Delta S$ (open circles) and ΔG (inverted filled triangles) dependence on a temperature ranging from 10 to 40°C, which permits determination of a ΔC_p value of $-320 (\pm 16)$ cal mol⁻¹ K⁻¹. Figure 7B shows the dependence of observed enthalpy on buffer ionization enthalpy (ΔH_{ion}) at 25 °C. Data fitting to Eq. 6 yielded a value of -0.47 for N_{H^+} (number of protons exchanged during the binding process) and -2.2 kcal mol⁻¹ for ΔH_{int} (intrinsic enthalpy).

Fig.7. Enzyme mechanism of *MtSK*.

Table 1. Steady-state kinetics constants of Shikimate Kinases (SKs) from different organisms.

	<i>MtSK</i> ¹	<i>MtSK</i> ²	<i>E. coli</i> SKI ²	<i>E. coli</i> SKII ²	EcSK ³
k_{cat} (s ⁻¹)	60 (± 8)	44 (± 2)		32	35
K_{MgATP} (μM)	112 (± 4)	83 (± 4)		160	620
K_{SKH} (μM)	650 (± 28)	410 (± 20)	20 x 10 ³	200	310
k_{cat}/K_{MgATP} (M ⁻¹ s ⁻¹)	5.4 (± 0.7) x 10 ⁵	5.3 x 10 ⁵		2.0 x 10 ⁵	5.6 x 10 ⁴
k_{cat}/K_{SKH} (M ⁻¹ s ⁻¹)	0.9 (± 0.1) x 10 ⁵	1.1 x 10 ⁵		1.6 x 10 ⁵	1.1 x 10 ⁵

¹ Results described here.

² adapted from reference [43].

³ SK from *Erwinia chrysanthemi*. (values taken from reference [54]).

Table 2. Thermodynamics parameters of formation of binary complexes between *MtSK* and substrate(s) or product(s).

	K_D (μM)	ΔH ($kcal\ mol^{-1}$)	ΔS ($cal\ mol^{-1}\ K^{-1}$)	ΔG ($kcal\ mol^{-1}$)	$-T\Delta S$ ($kcal\ mol^{-1}$)
SKH _{283.15 K, Hepes}	45 (\pm 13)	0.66 (\pm 0.04)	22.2 (\pm 6.5)	-5.6 (\pm 1.6)	-6.2 (\pm 1.8)
SKH _{298.15 K, Hepes}	181 (\pm 15)	-4.6 (\pm 0.2)	1.8 (\pm 0.2)	-5.1 (\pm 0.4)	-0.54 (\pm 0.05)
SKH _{313.15 K, Hepes}	235 (\pm 9)	-8.9 (\pm 0.1)	-11.9 (\pm 0.4)	-5.2 (\pm 0.2)	3.7 (\pm 0.1)
SKH _{298.15 K, Pipes}	135 (\pm 8)	-3.5 (\pm 0.1)	5.7 (\pm 0.3)	-5.2 (\pm 0.3)	-1.7 (\pm 0.2)
SKH _{298.15 K, Imidazole}	396 (\pm 47)	-6.4 (\pm 0.4)	-6.0 (\pm 0.7)	-4.6 (\pm 0.2)	1.8 (\pm 0.1)
ATP	196 (\pm 29)	-5.1 (\pm 0.3)	-0.15 (\pm 0.02)	-5.1 (\pm 0.8)	0.044 (\pm 0.007)
ADP	562 (\pm 20)	-12.4 (\pm 0.2)	-27 (\pm 1)	-4.4 (\pm 0.2)	7.9 (\pm 0.2)

K_D represents the equilibrium dissociation constant, ΔH is the binding enthalpy, ΔS is the binding entropy, ΔG is the Free Gibbs energy, and $-T\Delta S$ is the negative term for temperature (in Kelvin) times binding entropy.

Table 3. Hydrophobic and vibrational thermodynamic parameters of *Mt*SK:SKH binary complex formation.

T (K)	ΔH_H (kcal mol ⁻¹)	ΔH_V (kcal mol ⁻¹)	ΔS_H (cal mol ⁻¹ K ⁻¹)	ΔS_V (cal mol ⁻¹ K ⁻¹)	ΔC_{pH} (kcal mol ⁻¹ K ⁻¹)	ΔC_{pV} (kcal mol ⁻¹ K ⁻¹)	ΔG_H (kcal mol ⁻¹ K ⁻¹)	ΔG_V (kcal mol ⁻¹ K ⁻¹)
283.15	6.7	-6.0	72	-42	-278	-40	-13	5.9
298.15	5.2	-9.8	66	-65	-257	-61	-17	9.6
313.15	2.0	-11	65	-69	-252	-66	-18	10

ΔC_p represents the heat capacity; the H and V subscripts represent, respectively, the hydrophobic and vibrational contributions.

Capítulo 3

Considerações Finais

A tuberculose, ocasionada pelo bacilo *Mycobacterium tuberculosis*, representa um grande problema de saúde global devido a sua alta taxa de incidência e prevalência, além de casos de coinfeção reportados pela Organização Mundial da Saúde. Estima-se que em 2009 ocorreram 9,2 milhões de novos casos e 1,7 milhão de mortes (WHO, 2010) em contraste aos 8,7 milhões de novos casos e 1,4 milhão de mortes encontrados em 2011 (WHO, 2012). Apesar da diminuição de novos casos nos últimos anos, o surgimento de novas cepas resistentes tem tornado o quadro preocupante, aonde 3,7% (320 000) dos novos casos e 20% de casos tratados em 2011 foram diagnosticados como MDR (WHO, 2012) em contraste aos 30 000 casos de MDR diagnosticados em 2008 (WHO, 2010). Devido ao aumento na incidência de casos resistentes, o desenvolvimento de novas drogas contra o bacilo da tuberculose tem se mostrado um campo de pesquisa extremamente importante para a saúde global a curto e longo prazo. O desenvolvimento racional de novas drogas tem como base o estudo dos mecanismos relacionados às enzimas candidatas a alvo molecular. Adicionalmente, os inibidores enzimáticos possuem uma parcela de 25% do mercado de medicamentos nos Estados Unidos (Robertson 2005; Robertson 2007). De acordo com a BBC, em 2010 o mercado mundial de inibidores de quinases alcançou a marca de 28,1 bilhões de dólares, e aproximadamente 29,1 bilhões de dólares em 2011. Acredita-se que em 2016 esse valor suba para 40,2 bilhões de dólares (BBC, 2012). O mercado americano alcançou a marca de 10,8 e 10,4 bilhões de dólares em 2010 e 2011 respectivamente, e se tem uma estimativa que o valor subirá para 11,6 bilhões de dólares em 2016 (BBC, 2012). Na busca por uma enzima alvo, a via metabólica do chiquimato foi escolhida devido a sua essencialidade para a viabilidade do bacilo e a sua ausência no hospedeiro humano, sendo assim um promissor alvo seletivo (Parrish, 2002). Embasado nos dados preocupantes relacionados à infecção e desenvolvimento da tuberculose, na grande

importância das enzimas como alvo molecular para o desenvolvimento de drogas e tendo em vista a relevância das enzimas classificadas como quinases nos mercados de medicamentos mundial e americano, este trabalho versou sobre os mecanismos cinético e termodinâmico além de características estruturais relacionados à enzima *MtSK*. O desenvolvimento de um protocolo de purificação, identificação e a integridade da enzima *MtSK*, forneceram embasamento para realização de ensaios de cinética em estado-estacionário, que permitiram a identificação do mecanismo empregado pela enzima durante a catálise da reação utilizando os substratos naturais e as suas constantes. A determinação das constantes cinéticas indicaram que a enzima *MtSK* deve ser mais propriamente classificada como uma Chiquimato quinase do tipo II codificada pelo gene *aroL*, devido a maior similaridade nos valores cinéticos encontrados em comparação às enzimas ortólogas codificadas pelos genes *aroK* e *aroL* em *Escherichia coli*. Além disso, foram realizados estudos termodinâmicos através de calorimetria de titulação isotérmica a fim de observar a formação dos complexos *MtSK* com os substratos/produtos naturais, permitindo assim a definição mais adequada do mecanismo enzimático e as assinaturas termodinâmicas na interação proteína ligante. As assinaturas termodinâmicas identificaram que a enzima realiza uma adição ordenada aleatória na adição dos substratos e uma liberação ordenada sequencial na liberação dos produtos, tendo como primeiro produto a ser liberado o S3P, devido a sua incapacidade de se ligar na enzima livre. Adicionalmente, foi possível observar que a ligação do SKH no complexo $Mg^{2+}ATP:MtSK$ produziu um valor de energia livre final menos favorável do que a sua ligação na enzima livre, indicando assim uma cooperatividade negativa, ou seja, o ATP dificulta a ligação do SKH no sítio ativo. Devido à capacidade de ligação do SKH na enzima livre, ensaios de formação do complexo binário *MtSK:SKH* foram realizados em condições experimentais variadas. Primeiramente, ensaios termodinâmicos foram

realizados em condições experimentais idênticas às utilizadas na identificação do mecanismo enzimático, tendo como única variável a temperatura. Esses ensaios permitiram a identificação da capacidade calorífica em pressão constante, que indicou a dessolvatação de grupos apolares e um efeito hidrofóbico importante na formação do complexo. Esses dados foram confirmados através do modelo estrutural desenvolvido neste trabalho. Por final, a formação do complexo foi observada tendo como variável o tampão de reação. Este ensaio nos permitiu a identificação da transferência de 1 próton do complexo *MtSK:SKH* para o solvente, indicando assim os aminoácidos arg 38 e 156 encontrados no modelo estrutural construído neste trabalho, como fonte de prótons, tendo assim um papel importante na formação do complexo. Estes aminoácidos foram indicados como fonte de prótons devido ao seu grau de ionização, calculado pelo valor do pKa teórico no pH utilizado nas reações e pelas ligações de hidrogênio observadas no modelo estrutural. Estes dados foram agrupados e submetidos à revista PLoS ONE que após revisão aceitou o trabalho para publicação. Os resultados produzidos nesta tese permitiram a identificação de características cruciais para o desenvolvimento de inibidores com ação seletiva tendo como alvo a enzima *MtSK*, acrescentando dados importantes sobre a reação catalisada e aminoácidos importantes na formação do complexo *MtSK:SKH*. O SKH pode por fim, ser utilizado como estrutura inicial para o desenvolvimento de moléculas de ação inibitória competitiva.

Referências

- Bentley, R., *Crit. Rev. Biochem. Mol. Biol.*; 1990; 25, 307-384.
- Business Communications Company (BCC), *Kinase inhibitors: Global Markets*; 2012.
- Campbell, S.A., Richards, T. A., Mui, E.J., Samuel, B.U., Coggins, J.R., McLeod, R., Roberts, C. W.; *Int. J. Parasitol.*; 2004; 34,5-13.
- Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher C. et al; *Nature*; 1998; 393, 537-544.
- Dhaliwal, B., C.E. Nichols, J. Ren, M. Lockyer, I. Charles, A.R. Hawkins, D.K. Stammers, *FEBS Lett.*; 2004; 574, 49-54.
- Dias, M.V., Faím, L.M., Vasconcelos I.B, Oliveira J.S., Basso, L.A., Santos D.S., Azevedo, W.F.Jr, *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.*; 2007; 63, 1-6.
- Ducati, R.G., Basso, L.A., Santos, D.S.; *Current drug targets*; 2007; 3, 423-435.
- Goodman & Gilman A, et al. *As bases farmacológicas da terapêutica*. Rio de Janeiro. Ed. McGraw-Hill, 2006: 1821p;
- Haq, I.; *Calorimetry in the fast lane: The use of ITC for obtaining enzyme kinetics constants*. Microcal, LLC application note. 2002.
- Hargreaves S., *WHO report highlights alarming rise of resistant tuberculosis*. 2008; 8: 220;
- Hartmann, M.D., G.P. Bourenkov, A. Oberschall, N. Strizhov, H.D. Bartunik, J. *Mol. Biol.*; 2006; 364, 411-423.
- Herman, K.M and Weaver, L.M; *Annu. Rev. Plant Physiol. Plant Mol. Biol.*;1999; 50;473–503.
- Keeling, P.J., Palmer J.D., Donald, R.G., Roos, D.S., Waller, R.F., McFadden. G. I. *Nature*; 1999, 397:219–220.
- Laemmli, U.K., *Cleavage of structural proteins during the assembly of the head of bacteriophage T4*, *Nature.*;1970; 227, 680-685.
- McConkey, G. A., *Antimicrob. Agents Chemother.* 1999; 43; 175–177.
- McConkey, G. A., J. W. Pinney, D. R. Westhead, K. Plueckhahn, T. B. Fitzpatrick, P. Macheroux, B. Kappes. *Trends Parasitol*; 2004; 20:60–65.

- Parrish, T., Stoker, N.G., *Microbiology*; 2002; 148, 3069–3077
- Parrish, N.M., Dick, J.D, Bishai, W. R., Mechanisms of latency in *Mycobacterium tuberculosis*, 1998, 6 , 107-112;
- Pereira, J.H., Oliveira J.S., F. Canduri, M.V. Dias, M.S. Palma, L.A. Basso, D.S. Santos, W.F.Jr. Azevedo, *Acta Crystallogr. D Biol. Crystallogr.*; 2004; 60, 2310-2319.
- Roberts, F., C. W. Roberts, J. J. Johnson, D. E. Kyle, T. Krell, J. R. Coggins, G. H. Coombs, W. K. Milhous, S. Tzipori, D. J. Ferguson, D. Chakrabarti, R. McLeod. *Nature*; 1998; 393,801–805.
- Roberts. C. W., F. Roberts, R. E. Lyons, M. J. Kirisits, E. J. Mui, J. et al.; *J. Infect. Dis.* 2002; 185(Suppl. 1), S25–S36.
- Robertson J G, Mechanistic basis of enzyme-targeted drugs, *Biochem.*, 2005; 44, 5561-5571.
- Robertson J G, Enzymes as a special class of therapeutic target: clinical drugs and modes of action, *Curr. Opin. Struct. Biol.*, 2007; 17, 674-679.
- World Health Organization (WHO), *Global Tuberculosis Control: a short update to the 2009 report*; 2010.
- World Health Organization (WHO), *Global Tuberculosis Report*, 2012.
- Yan, H., Tsai, M.D.; *Adv. Enzymol. Relat. Areas Mol. Biol.*; 1999, 73,:103-134

Anexos

Anexo A

Kinetic mechanism and energetics of nucleotide binding to *Mycobacterium tuberculosis* Cytidine Monophosphate Kinase.
Biophysical chemistry, 2013.
(Artigo Submetido)

Léia Jaskulski, Leonardo A. Rosado,
Diana C. Rostirolla, Diógenes S.
Santos, Luiz A. Basso.

*Manuscript

[Click here to view linked References](#)

1 Kinetic mechanism and energetics of binding of phosphoryl group acceptors to

2 *Mycobacterium tuberculosis* Cytidine Monophosphate Kinase

3

4 Léia Jaskulski^{1,2,4}, Leonardo A. Rosado^{1,3,4}, Diana C. Rostirolla^{1,2}, Diógenes S. Santos^{1,2,*},

5 Luiz A. Basso^{1,2,*}

6

7 ¹Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de

8 Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio

9 Grande do Sul (PUCRS), Av. Ipiranga 6681, Porto Alegre, RS 90619-900, Brazil.

10 ²Programa de Pós-Graduação em Medicina e Ciências da Saúde, PUCRS, Av. Ipiranga 6681,

11 Porto Alegre, RS 90619-900, Brazil.

12 ³Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Av. Ipiranga 6681,

13 Porto Alegre, RS 90619-900, Brazil.

14 ⁴ These authors contributed equally to this work.

15

16 Running title: Kinetics and thermodynamics of *M. tuberculosis* CMK

17

18 *Corresponding authors: Luiz A. Basso or Diogenes S. Santos

19 Av. Ipiranga 6681 – Tecnopuc – Prédio 92A, ZIP CODE 90619-900, Porto Alegre, RS, Brazil.

20 Phone/Fax: +55-51-33203629; E-mail addresses: luiz.basso@pucrs.br or diogenes@pucrs.br

21

22 E-mail addresses of co-authors:

23 Léia Jaskulski: lejask@hotmail.com

24 Diana C. Rostirolla: diana_rostirolla@yahoo.com.br

25 Leonardo A. Rosado: leo.rosado@gmail.com

26

Anexo B

Biochemical characterization of uracil phosphoribosyltransferase from *Mycobacterium tuberculosis*. PLoS ONE, 2013.
(Artigo Aceito)

Anne Drumond Villela, Rodrigo Gay Ducati, Leonardo Astolfi Rosado, Carlos Bloch Junior, Maura Vianna Prates, Carlos Henrique Inacio Ramos, Luiz Augusto Basso, Diógenes Santiago Santos.

Biochemical Characterization of Uracil Phosphoribosyltransferase from *Mycobacterium tuberculosis*

Anne Drumond Villela^{1,2}, Rodrigo Gay Ducati¹, Leonardo Astolfi Rosado^{1,2,3}, Carlos Junior Bloch⁴, Maura Vianna Prates⁴, Danieli Cristina Gonçalves^{5,6}, Carlos Henrique Inacio Ramos⁶, Luiz Augusto Basso^{1,2*}, Diogenes Santiago Santos^{1,2*}

1 Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil, **2** Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil, **3** Programa de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil, **4** Laboratório de Espectrometria de Massa, Empresa Brasileira de Pesquisa Agropecuária - Recursos Genéticos e Biotecnologia, Estação Parque Biológico, Brasília, Federal District, Brazil, **5** Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil, **6** Instituto de Química, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil

Abstract

Uracil phosphoribosyltransferase (UPRT) catalyzes the conversion of uracil and 5-phosphoribosyl- α -1-pyrophosphate (PRPP) to uridine 5'-monophosphate (UMP) and pyrophosphate (PP_i). UPRT plays an important role in the pyrimidine salvage pathway since UMP is a common precursor of all pyrimidine nucleotides. Here we describe cloning, expression and purification to homogeneity of *upp*-encoded UPRT from *Mycobacterium tuberculosis* (MtUPRT). Mass spectrometry and N-terminal amino acid sequencing unambiguously identified the homogeneous protein as MtUPRT. Analytical ultracentrifugation showed that native MtUPRT follows a monomer-tetramer association model. MtUPRT is specific for uracil. GTP is not a modulator of MtUPRT activity. MtUPRT was not significantly activated or inhibited by ATP, UTP, and CTP. Initial velocity and isothermal titration calorimetry studies suggest that catalysis follows a sequential ordered mechanism, in which PRPP binding is followed by uracil, and PP_i product is released first followed by UMP. The pH-rate profiles indicated that groups with pK values of 5.7 and 8.1 are important for catalysis, and a group with a pK value of 9.5 is involved in PRPP binding. The results here described provide a solid foundation on which to base *upp* gene knockout aiming at the development of strategies to prevent tuberculosis.

Citation: Villela AD, Ducati RG, Rosado LA, Bloch CJ, Prates MV, et al. (2013) Biochemical Characterization of Uracil Phosphoribosyltransferase from *Mycobacterium tuberculosis*. PLoS ONE 8(2): e56445. doi:10.1371/journal.pone.0056445

Editor: Beata G. Vertessy, Institute of Enzymology of the Hungarian Academy of Science, Hungary

Received: April 25, 2012; **Accepted:** January 14, 2013; **Published:** February 12, 2013

Copyright: © 2013 Villela et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by funds of Decit/SCTIE/MS-MCT-CNPq-FNDCT-CAPES to National Institute of Science and Technology on Tuberculosis (INCT-TB) to DSS and LAB. LAB and DSS also acknowledge financial support awarded by FAPERGS-CNPq-PRONEX-2009 (Fundação de Amparo Pesquisa do estado do Rio Grande do Sul). CB acknowledges financial support from "Embrapa Recursos Genéticos e Biotecnologia", Brazil. CHIR acknowledges financial support from FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo). LAB (CNPq, 520182/99-5), DSS (CNPq, 304051/1975-06), CBJ (304034/2008-8), and CHIR are Research Career Awardees of the National Research Council of Brazil (CNPq). RGD was a post-doctoral fellow of CNPq (The National Council for Scientific and Technological Development). ADV and LAR acknowledge scholarships awarded by CNPq (The National Council for Scientific and Technological Development). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: luiz.basso@pucrs.br (LAB); diogenes@pucrs.br (DSS)

Anexo C

Role of Serine140 in the mode of action of *Mycobacterium tuberculosis* β -Ketoacyl-ACP reductase (MabA). BMC Research Notes, 2012. (Artigo Publicado)

Leonardo A. Rosado, Rafael Andrade Caceres, Walter Filgueira de Azevedo, Luiz A Basso and Diógenes S. Santos.

SHORT REPORT

Open Access

Role of Serine140 in the mode of action of *Mycobacterium tuberculosis* β -ketoacyl-ACP Reductase (MabA)

Leonardo A Rosado^{1,2,4}, Rafael Andrade Caceres^{2,3}, Walter Filgueira de Azevedo Jr^{3,4}, Luiz A Basso^{1,4*} and Diógenes S Santos^{1,4*}

Abstract

Background: Tuberculosis (TB) still remains one of the most deadly infectious diseases in the world. *Mycobacterium tuberculosis* β -ketoacyl-ACP Reductase (MabA) is a member of the fatty acid elongation system type II, providing precursors of mycolic acids that are essential to the bacterial cell growth and survival. MabA has been shown to be essential for *M. tuberculosis* survival and to play a role in intracellular signal transduction of bacilli.

Findings: Here we describe site-directed mutagenesis, recombinant protein expression and purification, steady-state kinetics, fluorescence spectroscopy, and molecular modeling for S140T and S140A mutant MabA enzymes. No enzyme activity could be detected for S140T and S140A. Although the S140T protein showed impaired NADPH binding, the S140A mutant could bind to NADPH. Computational predictions for NADPH binding affinity to WT, S140T and S140A MabA proteins were consistent with fluorescence spectroscopy data.

Conclusions: The results suggest that the main role of the S140 side chain of MabA is in catalysis. The S140 side chain appears to also play an indirect role in NADPH binding. Interestingly, NADPH titrations curves shifted from sigmoidal for WT to hyperbolic for S140A, suggesting that the S140 residue may play a role in displacing the pre-existing equilibrium between two forms of MabA in solution. The results here reported provide a better understanding of the mode of action of MabA that should be useful to guide the rational (function-based) design of inhibitors of MabA enzyme activity which, hopefully, could be used as lead compounds with anti-TB action.

Keywords: *Mycobacterium tuberculosis*, β -Ketoacyl-ACP Reductase, MabA, Site-directed mutagenesis, Enzyme activity, Fluorescence spectroscopy, Molecular modeling

Anexo D

Recombinant *Erwinia carotovora* L-asparaginase II production in *Escherichia coli* fed-batch cultures. *Brazilian Journal of Chemical Engineering*, 2012.
(Artigo Aceito)

Gustavo Roth, José E.S. Nunes, Leonardo A. Rosado, Cristiano V. Bizarro, Giandra Volpato, Cláudia P. Nunes, Gaby Renard, Luiz A. Basso, Diógenes S. Santos, Jocelei M. Chies.

Recombinant *Erwinia carotovora* L-asparaginase II production in *Escherichia coli* fed-batch cultures

Gustavo Roth^{1,3}, José ES Nunes^{1,3}, Leonardo A Rosado^{1,2}, Cristiano V Bizarro², Giandra Volpato^{3,4}, Cláudia P Nunes³, Gaby Renard³, Luiz A Basso^{1,2,3}, Diógenes S Santos^{1,2,3}, Joceli M Chies^{3,*}

¹Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul. Av. Ipiranga, 6690, Partenon, Porto Alegre, ZC 90610000, Brazil

²Centro de Pesquisas em Biologia Molecular e Funcional, Instituto de Pesquisas Biomédicas, Pontifícia Universidade Católica do Rio Grande do Sul. Av. Ipiranga, 6681, Tecnopuc, Prédio 92A, Partenon, Porto Alegre, ZC 90619900, Brazil

³Quatro G Pesquisa e Desenvolvimento Ltda. Av. Ipiranga, 6681, Tecnopuc, Prédio 92A, Partenon, Porto Alegre, ZC 90619900, Brazil

⁴Instituto Federal de Educação, Ciência e Tecnologia do Rio Grande do Sul. Rua Ramiro Barcelos, 2777, Santana, Porto Alegre, ZC 90035007, Brazil

Anexo E

Molecular, kinetic and thermodynamic characterization of *Mycobacterium tuberculosis* orotate phosphoribosyltransferase. Molecular Biosystems, 2012. (Artigo Publicado)

Ardala Breda, Leonardo Astolfi Rosado, Daniel Macedo Lorenzini, Luiz Augusto Basso and Diógenes Santiago Santos.

Molecular, kinetic and thermodynamic characterization of *Mycobacterium tuberculosis* orotate phosphoribosyltransferase^{†‡}

Ardala Breda,^{abc} Leonardo Astolfi Rosado,^{abd} Daniel Macedo Lorenzini,^{ab}
Luiz Augusto Basso^{*abc} and Diógenes Santiago Santos^{*abc}

Received 27th September 2011, Accepted 18th October 2011

DOI: 10.1039/c1mb05402c

Tuberculosis (TB) is a chronic infectious disease caused mainly by *Mycobacterium tuberculosis*. The worldwide emergence of drug-resistant strains, the increasing number of infected patients among immune compromised populations, and the large number of latent infected individuals that are reservoir to the disease have underscored the urgent need of new strategies to treat TB. The nucleotide metabolism pathways provide promising molecular targets for the development of novel drugs against active TB and may, hopefully, also be effective against latent forms of the pathogen. The orotate phosphoribosyltransferase (OPRT) enzyme of the *de novo* pyrimidine synthesis pathway catalyzes the reversible phosphoribosyl transfer from 5'-phospho- α -D-ribose 1'-diphosphate (PRPP) to orotic acid (OA), forming pyrophosphate and orotidine 5'-monophosphate (OMP). Here we describe cloning and characterization of *pyrE*-encoded protein of *M. tuberculosis* H37Rv strain as a homodimeric functional OPRT enzyme. The *M. tuberculosis* OPRT true kinetic constants for forward reaction and product inhibition results suggest a Mono-Iso Ordered Bi-Bi kinetic mechanism, which has not been previously described for this enzyme family. Absence of detection of half reaction and isothermal titration calorimetry (ITC) data support the proposed mechanism. ITC data also provided thermodynamic signatures of non-covalent interactions between substrate/product and *M. tuberculosis* OPRT. These data provide a solid foundation on which to base target-based rational design of anti-TB agents and should inform us how to better design inhibitors of *M. tuberculosis* OPRT.

Anexo F

Pyrimidin-2(1H)-ones based
inhibitors of *Mycobacterium
tuberculosis* orotate
phosphoribosyltransferase.
European Journal of Medicinal
Chemistry, 2012.
(Artigo Publicado)

Ardala Breda, Pablo Machado,
Leonardo Astolfi Rosado, André
Arigony Souto, Diógenes Santiago
Santos and Luiz Augusto Basso.



Original article

Pyrimidin-2(1H)-ones based inhibitors of *Mycobacterium tuberculosis* orotate phosphoribosyltransferase

Ardala Breda^{a,b,c}, Pablo Machado^{a,b,c}, Leonardo Astolfi Rosado^{a,b,d}, André Arigony Souto^{c,e}, Diógenes Santiago Santos^{a,b,c}, Luiz Augusto Basso^{a,b,c,*}

^aInstituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil

^bCentro de Pesquisas em Biologia Molecular e Funcional, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil

^cPrograma de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil


^dPrograma de Pós-Graduação em Medicina e Ciências da Saúde, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil

^eFaculdade de Química, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, Rio Grande do Sul, Brazil

HIGHLIGHTS

- ▶ Selection and optimization of inhibitors based on MtOPRT kinetic mechanism.
- ▶ Identification of MtOPRT inhibitors with nanomolar inhibition constant values.
- ▶ *In vitro* kinetic assays to characterize binding mode of inhibitors.
- ▶ Thermodynamic discrimination profiles of inhibitors assessed by ITC.
- ▶ Inhibitory activity of **13** is likely due to entropy optimization.

GRAPHICAL ABSTRACT



ARTICLE INFO

Article history:

Received 27 October 2011
Received in revised form
20 April 2012
Accepted 24 April 2012
Available online 30 April 2012

Keywords:

Mycobacterium tuberculosis
Tuberculosis
Pyrimidine
Orotate phosphoribosyltransferase

ABSTRACT

Tuberculosis (TB) is an ancient human chronic infectious disease caused mainly by *Mycobacterium tuberculosis*. The emergence of strains resistant to first and second line anti-TB drugs, associated with the increasing number of TB cases among HIV positive subjects, and the large number of individuals infected with latent bacilli have urged the development of new strategies to treat TB. Enzymes of nucleotide metabolism pathways provide promising molecular targets for the development of drugs, aiming at both active and latent TB. The orotate phosphoribosyltransferase (OPRT) enzyme catalyzes the synthesis of orotidine 5'-monophosphate from 5'-phospho- α -D-ribose 1'-diphosphate and orotic acid, in the *de novo* pyrimidine synthesis pathway. Based on the kinetic mechanism and molecular properties, here we describe the design, selection and synthesis of substrate analogs with inhibitory activity of *M. tuberculosis* OPRT (MtOPRT) enzyme. Steady-state kinetic measurements were employed to determine the mode of inhibition of commercially available and chemically derived compounds.

Abbreviations: TB, tuberculosis; MTB, *Mycobacterium tuberculosis*; OPRT, orotate phosphoribosyltransferase; QA, orotate; PRPP, α -D-5-phosphoribosyl-1-pyrophosphate; K_m , Michaelis–Menten constant; OMP, orotidine 5'-monophosphate; PP_i, pyrophosphate; UMP, uridine 5'-monophosphate; MtOPRT, *M. tuberculosis* OPRT; FTIR, Fourier transform infrared; ITC, isothermal titration calorimetry; UATR, universal attenuated total reflectance.

* Corresponding author. Instituto Nacional de Ciência e Tecnologia em Tuberculose, Pontifícia Universidade Católica do Rio Grande do Sul, Avenida Ipiranga 6900, Prédio 92A – TECNOPUC, 90619-900 Porto Alegre, RS, Brazil. Tel./fax: +55 51 3320 3629.

E-mail addresses: ardalabreda@gmail.com (A. Breda), pablomachado@mail@gmail.com (P. Machado), leo.rosado@gmail.com (L.A. Rosado), arigony@puccs.br (A.A. Souto), diogenes@puccs.br (D.S. Santos), luiz.basso@puccs.br (L.A. Basso).

Anexo G

Wild-Type
Phosphoribosylpyrophosphate
Synthase (PRS) from
Mycobacterium tuberculosis: A
Bacterial Class II PRS?
PlosOne, 2012.
(Artigo Publicado)

Ardala Breda, Leonardo K. B.
Martinelli, Cristiano V. Bizarro,
Leonardo A. Rosado,
Caroline B. Borges, Diógenes S.
Santos, Luiz A. Basso.

Wild-Type Phosphoribosylpyrophosphate Synthase (PRS) from *Mycobacterium tuberculosis*: A Bacterial Class II PRS?

Ardala Breda^{1,2}, Leonardo K. B. Martinelli^{1,2}, Cristiano V. Bizarro¹, Leonardo A. Rosado^{1,2},
Caroline B. Borges^{1,2}, Diógenes S. Santos^{1,2*}, Luiz A. Basso^{1,2*}

1 Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil, **2** Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Rio Grande do Sul, Brazil

Abstract

The 5-phospho- α -D-ribose 1-diphosphate (PRPP) metabolite plays essential roles in several biosynthetic pathways, including histidine, tryptophan, nucleotides, and, in mycobacteria, cell wall precursors. PRPP is synthesized from α -D-ribose 5-phosphate (R5P) and ATP by the *Mycobacterium tuberculosis* *prsA* gene product, phosphoribosylpyrophosphate synthase (*MtPRS*). Here, we report amplification, cloning, expression and purification of wild-type *MtPRS*. Glutaraldehyde cross-linking results suggest that *MtPRS* predominates as a hexamer, presenting varied oligomeric states due to distinct ligand binding. *MtPRS* activity measurements were carried out by a novel coupled continuous spectrophotometric assay. *MtPRS* enzyme activity could be detected in the absence of P_i . ADP, GDP and UMP inhibit *MtPRS* activity. Steady-state kinetics results indicate that *MtPRS* has broad substrate specificity, being able to accept ATP, GTP, CTP, and UTP as diphosphoryl group donors. Fluorescence spectroscopy data suggest that the enzyme mechanism for purine diphosphoryl donors follows a random order of substrate addition, and for pyrimidine diphosphoryl donors follows an ordered mechanism of substrate addition in which R5P binds first to free enzyme. An ordered mechanism for product dissociation is followed by *MtPRS*, in which PRPP is the first product to be released followed by the nucleoside monophosphate products to yield free enzyme for the next round of catalysis. The broad specificity for diphosphoryl group donors and detection of enzyme activity in the absence of P_i would suggest that *MtPRS* belongs to Class II PRS proteins. On the other hand, the hexameric quaternary structure and allosteric ADP inhibition would place *MtPRS* in Class I PRSs. Further data are needed to classify *MtPRS* as belonging to a particular family of PRS proteins. The data here presented should help augment our understanding of *MtPRS* mode of action. Current efforts are toward experimental structure determination of *MtPRS* to provide a solid foundation for the rational design of specific inhibitors of this enzyme.

Citation: Breda A, Martinelli LKB, Bizarro CV, Rosado LA, Borges CB, et al. (2012) Wild-Type Phosphoribosylpyrophosphate Synthase (PRS) from *Mycobacterium tuberculosis*: A Bacterial Class II PRS? PLoS ONE 7(6): e39245. doi:10.1371/journal.pone.0039245

Editor: Anil Kumar Tyagi, University of Delhi, India

Received: March 15, 2012; **Accepted:** May 22, 2012; **Published:** June 20, 2012

Copyright: © 2012 Breda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by funds of Decit/SCTIE/MS-MCT-CNPq-FNDCT-CAPEs to National Institute of Science and Technology on Tuberculosis (INCT-TB) to Diógenes S. Santos and Luiz Basso. Luiz Basso and Diógenes S. Santos also acknowledge financial support awarded by FAPERGS-PRONEX/CNPq-2009. (Fundação de Amparo À Pesquisa do Estado do Rio Grande do Sul - The National Council for Scientific and Technological Development.) Luiz Basso (CNPq, 520182/99-5) and Diógenes S. Santos (CNPq, 304051/1975-06) are Research Career Awardees of The National Council for Scientific and Technological Development (CNPq). Ardala Breda, Leonardo K. B. Martinelli, Cristiano V. Bizarro, Leonardo A. Rosado and Caroline B. Borges acknowledge scholarships awarded by The National Council for Scientific and Technological Development (CNPq) and The Higher Education Co-ordination Agency (CAPES). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: luiz.basso@pucrs.br (LB); diogenes@pucrs.br (DSS)

Anexo H

Molecular, kinetic, thermodynamic, and structural analyses of *Mycobacterium tuberculosis* hisD-encoded metal-dependent dimeric histidinol dehydrogenase (EC 1.1.1.23).

Archives of Biochemistry and Biophysics, 2011.
(Artigo Publicado)


José E.S. Nunes, Rodrigo G. Ducati
Ardala Breda, Leonardo A. Rosado,
Bibiana M. de Souza,
Mario S. Palma, Diógenes S. Santos
Luiz A. Basso.



Contents lists available at ScienceDirect

Archives of Biochemistry and Biophysics

journal homepage: www.elsevier.com/locate/yabbi



Molecular, kinetic, thermodynamic, and structural analyses of *Mycobacterium tuberculosis* *hisD*-encoded metal-dependent dimeric histidinol dehydrogenase (EC 1.1.1.23)

José E.S. Nunes^{a,b}, Rodrigo G. Ducati^a, Ardala Breda^{a,b}, Leonardo A. Rosado^{a,b}, Bibiana M. de Souza^c, Mario S. Palma^c, Diógenes S. Santos^{a,b,*}, Luiz A. Basso^{a,b,*}

^aCentro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto Nacional de Ciência e Tecnologia em Tuberculose (INCT-TB), Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Av. Ipiranga 6681, Porto Alegre 90619-900, RS, Brazil

^bPrograma de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto Alegre, RS, Brazil

^cInstituto de Biociências de Rio Claro, Universidade Estadual Paulista (UNESP), Avenida 24A, 1515, Rio Claro, SP 13506-900, Brazil

ARTICLE INFO

Article history:

Received 16 March 2011
and in revised form 26 May 2011
Available online 6 June 2011

Keywords:

Histidinol dehydrogenase
Mycobacterium tuberculosis
Metalloenzyme
Thermodynamic binding parameters
Enzyme mechanism
Molecular model

ABSTRACT

The emergence of drug-resistant strains of *Mycobacterium tuberculosis*, the major causative agent of tuberculosis (TB), and the deadly HIV-TB co-infection have led to an urgent need for the development of new anti-TB drugs. The histidine biosynthetic pathway is present in bacteria, archaeobacteria, lower eukaryotes and plants, but is absent in mammals. Disruption of the *hisD* gene has been shown to be essential for *M. tuberculosis* survival. Here we present cloning, expression and purification of recombinant *hisD*-encoded histidinol dehydrogenase (M_tHisD). N-terminal amino acid sequencing and electrospray ionization mass spectrometry analyses confirmed the identity of homogeneous M_tHisD. Analytical gel filtration, metal requirement analysis, steady-state kinetics and isothermal titration calorimetry data showed that homodimeric M_tHisD is a metalloprotein that follows a Bi Uni Uni Bi Ping-Pong mechanism. pH-rate profiles and a three-dimensional model of M_tHisD allowed proposal of amino acid residues involved in either catalysis or substrate(s) binding.

© 2011 Elsevier Inc. All rights reserved.